**IZBORNOM VEĆU MEDICINSKOG FAKULTETA U BEOGRADU**

Komisija za pripremu referata u sastavu:

1. Prof. dr Miloš Korać, redovni profesor Medinskog fakulteta u Beogradu

2. Prof. dr Ivana Milošević, vanredni profesor Medinskog fakulteta u Beogradu

3. Prof. dr Jasmina Poluga, vanredni profesor Medicinskog fakulteta u Beogradu

određena po Odluci br. 14579/1, donetoj na sednici Izbornog veća Medicinskog fakulteta u Beogradu održanoj 25.12.2024.godine, razmatrala je prijave na konkurs raspisan na internet stranici Medicinskog fakulteta u Beogradu dana 20.01.2025. godine za izbor 5 (pet) saradnika u zvanje KLINIČKOG ASISTENTA, za užu naučnu oblast INFEKTIVNE BOLESTI, i podnosi sledeći

**REFERAT**

Na raspisani konkurs javilo se pet kandidata:

1. Dr Aleksandra Barać, doktor medicinskih nauka, specijalista infektologije

2. Dr Ankica Vujović, doktor medicinskih nauka, specijalista infektologije

3. Dr Boris Jegorović, doktor medicinskih nauka, specijalista infektologije

4. Dr Marko Marković, doktor medicinskih nauka, specijalista infektologije

5. Dr Uroš Karić, specijalista infektologije

**1. Kandidat dr ALEKSANDRA BARAĆ, doktor medicinskih nauka, specijalista infektologije**

**A.** **OSNOVNI BIOGRAFSKI PODACI**

–Ime, srednje ime i prezime: Aleksandra (Milan) Barać

–Datum i mesto rođenja: 03.06.1985. Sremska Mitrovica

–Ustanova gde je zaposlen: Klinika za infektivne i tropske bolesti UKCS

–Zvanje / radno mesto: Lekar specijalista infektolog

–Uža naučna oblast: Infektivne bolesti

**B. STRUČNA BIOGRAFIJA, DIPLOME I ZVANJA**

**Osnovne studije**

–Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu

–Mesto i godina završetka, prosečna ocena: Beograd, 16.06.2010. godine, prosečna ocena 8,73

**Doktorat:**

–Naziv ustanove: Medicinski fakultet u Beogradu, Univerzitet u Beogradu

–Mesto i godina odbrane i članovi komisije: Beograd, 2015. godina, Prof. dr Dragana Janić (predsednik komisije), Prof. dr Predrag Minić (član komisije), Prof. dr Sandra Đurđević Pekić (član komisije), Prof. dr Zoran Rakočević (član komisije), Prof. dr Suzana Otašević (član komisije)

–Mentori: Prof. dr Vesna Tomić Spirić (komentor) i Prof. Dr Valentina Arsić Arsenijević (mentor)

–Naslov disertacije: “Evaluacija metode indukcije sinonazalnog sekreta za dokazivanje gljivica u sinusima u fiziološkim i patološkim stanjima kod pacijenata sa hroničnim rinosinuzitisima“.

–Uža naučna oblast: Fiziološke nauke.

**Specijalizacija:**

* Naziv: Infektivne bolesti
* Naziv ustanove: Medicinski fakultet Univerziteta u Beogradu
* Mesto i godina završetka, ocena i članovi komisije: Medicinski fakultet, Univerzitet u Beogradu, 29.01.2021, ocena 5, članovi komisije: Prof. dr Jovan Ranin, Prof. dr Jasmina Poluga, Prof. Dr Ksenija Bojović.

**Uža specijalizacija:**

* Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu
* Mesto, godina završetka i članovi komisije: Medicinski fakultet Univerziteta u Beogradu, 2023. godine, Prof. Dr Dragan Obradović (predsednik komisije), Prof. Dr Ljiljana Gojković Bukarica, Prof. dr Jovan Ranin, Mentor: Doc. Dr Dragana Srebro
* Naslov rada uže specijalizacije: Analiza terapijskog uspeha antivirusne terapije molnupiravirom na ishod lečenja COVID-19 pacijenata
* Uža naučna oblast: Klinička farmakologija i farmakoterapija

**Dosadašnji izbori u nastavna i naučna zvanja**

- 2011. god., Istraživač saradnik, Medicinski Fakultet Univerziteta u Beogradu

- 2016. god., Docent, Stomatološki fakultet u Pančevu

- 2017. god., Naučni saradnik, Medicinski Fakultet Univerziteta u Beogradu

- 2022. god., Klinički asistent, Medicinski fakultet Univerzitet u Beogradu

- 2023. god., Naučni savetnik, Medicinski Fakultet Univerziteta u Beogradu

**V. OCENA O REZULTATIMA PEDAGOŠKOG RADA**

**Osnovna nastava**

Dr Aleksandra Barać učestvuje u izvođenju nastave održavajući vežbe redovne nastave za studente sedmog i osmog semestra (240 časova godišnje) na Integrisanim akademskim studijama medicine za sticanje akademskog naziva doktor medicine, Medicinskog fakulteta Univerziteta u Beogradu. Kao klinički asistent dr Barać učestvuje i u izvođenju praktične nastave za studente Osnovnih akademskih studija sestrinstva. Kandidat takođe redovno učestvuje u izvođenju praktične nastave na engleskom jeziku. Uključen je i u izvođenje praktične nastave u okviru specijalističke nastave iz oblasti Infektivnih bolesti. Prema izveštaju Centra za obezbeđivanje kvaliteta, unapređenje nastave i razvoj medicinske edukacije Medicinskog fakulteta Univerziteta u Beogradu ocenjena je od strane studenata ocenom 5.00 (2023/2024) i 4.73 (2022/2023). Na kongresu studenata biomedicinskih nauka u Vrnjačkoj banji 2024. godine održala je panel diskusiju na temu »Preteće infektivne bolesti«.

Tokom 2016 god. Dr Barać je bila zaposlena na Stomatološkom fakultetu u Pančevu u svojstvu Docenta na katedri za Bazične nauke (Histologija i embriologija) gde je samostalno pripremala i vodila nastavu, predispitne vežbe i održavala ispite i na taj način stekla veliko pedagoško iskustvo.

**Nastava na engleskom jeziku**

Dr Barać učestvuje u izvođenju praktične nastave za studente osnovnih studija, nastave na engleskom jeziku po predviđenom planu u proteklom periodu. Takodje, od 2023. god. je angažovana na izvođenju praktične nastave za studente osnovnih studija, nastave na engleskom jeziku u Medicinskom Fakultetu u Foči, Univerzitetu u Istočnom Sarajevu. Dr Barać je stalni član Međunarodnog odbora za doktorske disertacije Univerziteta u Sasariju, Sardinija. Učestvovala je u više različitih projekata i međunarodnih saradnji kroz koje je ispoljila pozitivnu pedagošku stranu, kroz edukaciju studenata akademskih i doktorskih studija na srpskom i engleskom jeziku. Takođe Dr Barać je višegodišnji gostujući Profesor na Univerzitetu u Sasariju, Italija, gde svake godine održava nastavu za studente akademskih i doktorskih studija.

**Poslediplomska nastava**

Učestvovala je u izvođenju izborne nastave iz Medicinske mikologije na Medicinskom fakultetu Univerziteta u Beogradu u periodu od 2011. do 2015. godine. Sve vreme učestvuje i u stručnom usavršavanju specijalizanata u oblasti Infektivnih bolesti prenoseći im klinička znanja tokom boravka na odeljenjima Klinike za Infektivne bolesti UKCS.

**G. OCENA REZULTATA U OBEZBEĐIVANJU NAUČNO-NASTAVNOG PODMLATKA**

**Mentorstva**

**Mentor diplomskih radova:**

1. Student Vanja Terzić, tema „Novine u dijagnostici i lečenju sepse“, 2025. god. (u toku), Medicinski fakultet Univerziteta u Beogradu

2. Student Jelena Graovac, tema „Uloga i efikasnost novih antibiotika u lečenju bakterijskih urinarnih infkcija izazvanih multirezistentnim sojevima“, 2025. god. (u toku), Medicinski fakultet Univerziteta u Beogradu

**Mentor studentskih radova:**

1. Kristina Sekanić, tema "Jednogodišnje praćenje mikrobioloških izolata i profila rezistencije kod pacijenata sa pozitivnom hemokulturom u Univerzitetskom kliničkom centru Srbije", 2025. godine, MFUB, Beograd

2. Ana Mitić, tema „Razlike u kliničkim i laboratorijskim karakteristikama kod pacijenata obolelih od SARS-CoV2 virusa tokom različitih talasa pandemije“, 2024. godine, Medicinski fakultet Univerziteta u Beogradu

3. Tea Milinković, (nagrađen kao najbolji rad iz oblasti Infektologije) tema „Analiza laboratorijskih, kliničkih i radioloških karakteristika pacijenata sa infektivnim spondilodiscitisom“, 2024. godine, Medicinski fakultet Univerziteta u Beogradu

4. Tea Milinković, tema „Nejasno febrilno stanje: dijagnostički pristup i smernice za diferencijalne dijagnoze“, 2023. godine, Medicinski fakultet Univerziteta u Beogradu

**Komentor doktorske disertacije:**

1. Dr Jovan Rajić, Klinika za Hematologiju UKCS, tema „Korelacija kliničkih, laboratorijskih, mikrobioloških i radiografskih nalaza kod pacijenata sa akutnom leukemijom i aspergilozom pluća: prognostički i prediktivni značaj skoring sistema“, prijavljena tema 2023. godine, Medicinski fakultet Univerziteta u Beogradu

**Član komisije za odbranu diplomskih radova:**

1. Almas Ahmenulić (ME 77/17), tema „Biological Therapy in Asthma “, datum odbrane 24.11.2023. godine, Medicinski fakultet Univerziteta u Beogradu

2. Ana Dražić (195/17), tema „Imunomodulatorna terapija u sepsi“, datum odbrane 19.06.2023. godine, Medicinski fakultet Univerziteta u Beogradu

**Član komisije za izbor u naučno zvanje:**

1. Naučni saradnik Dr Miljana Jovandarić, Klinika za Ginekologiju i akušerstvo, Univerzitetski Klinički Centar Srbije, 2019, Medicinski fakultet Univerziteta u Beogradu

Sarađivala je u više navrata sa Centrom za stručni i naučno-istraživački rad studenata kao recenzent studentskih radova.

**D. NAUČNI I STRUČNI RAD**

**a) Spisak objavljenih naučnih i stručnih radova**

**ORIGINALNI RADOVI INEXTENSO U ČASOPISIMA SA JCR (JOURNAL CITATION REPORTS) LISTE:**

1. Gupta N, Grobusch MP, Jokelainen P, Wyllie AL, **Barac A**, Mora-Rillo M, Gkrania-Klotsas E, Pellejero-Sagastizabal G, Paño-Pardo JR, Duizer E, Lescure FX. Poliomyelitis in Gaza. Clin Microbiol Infect. 2025; 31(2):154-156. **M21a; IF: 10.9**
2. Jokelainen P, Wyllie AL, Gupta N, **Barac A**, Gkrania-Klotsas E, Bulescu C, Paño-Pardo JR, Mora-Rillo M, Grobusch MP, Lescure FX. Complex mpox situation, 2024. Clin Microbiol Infect. 2025; 31(2):152-153. **M21a; IF: 10.9**
3. Righi E, Mirandola M, Grossi AA, Akova M, Tacconelli E, Fratucello A, Nasim A, **Barac A**, Yahav D. Infectious diseases ethics: a worldwide survey. Clin Microbiol Infect. 2025; 31(2):282-289. **M21a; IF: 10.9**
4. Grobusch MP, Jokelainen P, Wyllie AL, Gupta N, Paño-Pardo JR, **Barac A**, Bulescu C, Pellejero-Sagastizábal G, Goorhuis A, Lescure FX, Gkrania-Klotsas E, Mora-Rillo M. Marburg virus disease outbreak in Rwanda, 2024. Clin Microbiol Infect. 2025 Feb;31(2):161-163. **M21a; IF: 10.9**
5. Righi E, Yahav D, Nasim A, Akova M, **Barac A,** Scudeller L, Nagavci B, Armellini M, Zanchi C, Shirin N, Tunali V, Paño-Pardo JR, Rodríguez-Baño J, Jamrozik E. Incorporating ethics into infectious disease clinical practice guidelines. Clin Microbiol Infect. 2025: S1198-743X(25)00013-8. **M21a; IF: 10.9**
6. **Barac A**, Stjepanovic M, Krajisnik S, Stevanovic G, Paglietti B, Milosevic B. Dermatophytes: Update on Clinical Epidemiology and Treatment. Mycopathologia. 2024; 189(6):101. **M21; IF: 5.5**
7. Mijatović S, Štajner T, Čalovski IČ, Dubljanin E, Bobić B, Leković Z, **Barać A**, Džamić AM. Human infections by Hymenolepis diminuta in Europe: a case report and literature review. Trans R Soc Trop Med Hyg. 2024; 118(9):580-588. **M23; IF: 2.2**
8. Neuböck MJ; for CPAnet; Günther G, **Barac A**, Davidsen JR, Laursen CB, Agarwal R, Sehgal IS, Lange C, Salzer HJF. Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease. Semin Respir Crit Care Med. 2024; 45(1):102-113. **M22; IF: 3.92.**
9. Didarlu H, Mahami-Oskouei M, Varshochi M, Hatam-Nahavandi K, Shahrivar F, Bahadory S, **Barac A**, Ahmadpour E. Prevalence of Cryptosporidium and microsporidial infection in HIV-infected individuals. Trans R Soc Trop Med Hyg. 2024; 118(4):293-298. **M22; IF: 2.46.**
10. Donadu MG, Ferrari M, Behzadi P, Trong Le N, Usai D, Fiamma M, Battah B, **Barac A**, Bellardi MG, Hoai TN, Mazzarello V, Rubino S, Cappuccinelli P, Zanetti S. Multifactorial action of lavender and lavandin oils against filamentous fungi. Nat Prod Res. 2024; 31:1-9. **M22; IF: 2.48.**
11. Barzgar G, Ahmadpour E, Kohansal MH, Mehrani Moghaddam S, Jafari Koshki T, **Barac A**, Nissapatorn V, Paul AK, Micić J. Seroprevalence and risk factors of Toxoplasma gondii infection among pregnant women. J Infect Dev Ctries. 2024; 18(1):60-65. **M23; IF: 2.55.**
12. Ahmadpour E, Valilou S, Ghanizadegan MA, Seyfi R, Hosseini SA, Hatam-Nahavandi K, Hosseini H, Behravan M, **Barac A**, Morovati H. Global prevalence, mortality, and main characteristics of HIV-associated pneumocystosis: A systematic review and meta-analysis. PLoS One. 2024; 19(3):e0297619. **M22; IF: 3.75.**
13. Colovic N, Ljubicic J, Kostic D, **Barac A**, Jurisic V. Disseminated cerebral cryptococcosis after silent West Nile virus infection in a patient with polycythaemia vera: a case report and review of the literature. SAGE Open Medical Case Reports. 2024; 12:2050313X241262145.  **M23; IF: 0.8.**
14. **Barac A**, Vujovic A, Peric J, Tulic I, Stojanovic M, Stjepanovic M. Rethinking aspergillosis in the era of microbiota and mycobiota. Mycopathologia. 2024; 189(4):49. **M21; IF: 5.5**
15. Righi E, Mirandola M, Grossi AA, Akova M, Tacconelli E, Fratucello A, Nasim A, **Barac A**, Yahav D. Infectious diseases ethics: a worldwide survey. Clin Microbiol Infect. 2024: S1198-743X(24)00503-2. **M21a; IF: 10.9.**
16. Salmanton-García J, Cornely OA, Stemler J, **Barać A**, Steinmann J, Siváková A, Akalin EH, Arikan-Akdagli S, Loughlin L, Toscano C, Narayanan M, Rogers B, Willinger B, Akyol D, Roilides E, Lagrou K, Mikulska M, Denis B, Ponscarme D, Scharmann U, Azap A, Lockhart D, Bicanic T, Kron F, Erben N, Rautemaa-Richardson R, Goodman AL, Garcia-Vidal C, Lass-Flörl C, Gangneux JP, Taramasso L, Ruiz M, Schick Y, Van Wijngaerden E, Milacek C, Giacobbe DR, Logan C, Rooney E, Gori A, Akova M, Bassetti M, Hoenigl M, Koehler P. Attributable mortality of candidemia - Results from the ECMM Candida III multinational European Observational Cohort Study. J Infect. 2024; 89(3):106229. **M21a; IF: 14.3.**
17. Gmizic II, **Barac A**, Todorovic N, Sabanovic M, Kekic N, Boskovic N, Vujovic A, Nikolic N, Knezevic N, Milosevic I, Stevanovic G. Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study. J Infect Dev Ctries. 2024; 18(5):694-700. **M23; IF: 1.4.**
18. Pantić N, **Barać A**, Mano V, Dedeić-Ljubović A, Malkodanski I, Jaksić O, Gkentzi D, Mitrović M, Munteanu O, Šišević D, Stojanoski Z, Popescu O, Todorović J, Cornely OA, Salmanton-García J; Collaborators. Mapping the path to excellence: Evaluation of the diagnostic and treatment tools for invasive fungal infections in the balkans. J Infect Public Health. 2024; 17(8):102493. **M21; IF: 4.7.**
19. Arendrup MC, Arikan-Akdagli S, Jørgensen KM, **Barac A**, Steinmann J, Toscano C, Arsenijevic VA, Sartor A, Lass-Flörl C, Hamprecht A, Matos T, Rogers BRS, Quiles I, Buil J, Özenci V, Krause R, Bassetti M, Loughlin L, Denis B, Grancini A, White PL, Lagrou K, Willinger B, Meijer EFJ, Gangneux JP, Lockhart DEA, Khanna N, Logan C, Scharmann U, Desoubeaux G, Roilides E, Talento AF, van Dijk K, Koehler P, Salmanton-García J, Cornely OA, Hoenigl M. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern. 2023; 87(5):428-437. **M21a; IF: 38.63.**
20. Egger M, Salmanton-García J, **Barac A**, Gangneux JP, Guegan H, Arsic-Arsenijevic V, Matos T, Tomazin R, Klimko N, Bassetti M, Hammarström H, Meijer EFJ, Meis JF, Prattes J, Krause R, Resat Sipahi O, Scharmann U, White PL, Desoubeaux G, García-Rodríguez J, Garcia-Vidal C, Martín-Pérez S, Ruiz M, Tumbarello M, Talento AF, Rogers B, Lagrou K, van Praet J, Arikan-Akdagli S, Arendrup MC, Koehler P, Cornely OA, Hoenigl M; Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study. Mycopathologia. 2023; 188(6):983-994. **M21; IF: 5.5.**
21. **Barac A**, Vujovic A, Drazic A, Stevanovic G, Paglietti B, Lukic K, Stojanovic M, Stjepanovic M. Diagnosis of Chronic Pulmonary Aspergillosis: Clinical, Radiological or Laboratory? J Fungi (Basel). 2023 6;9(11):1084. **M21; IF: 5.816.**
22. Wunrow HY…**Barac A**…Kyu HH. GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023; 22(8):685-711. **M21a; IF: 59.935.**
23. Markovic-Vasiljkovic B, Janovic A, Antic S, **Barac A**, Bracanovic M, Peric A, Bracanovic D. Assessment of chronic rhinosinusitis severity indicators: radiological and clinical perspective. J Infect Dev Ctries. 2023; 17(6):854-859. **M23; IF: 2.55.**
24. Stojanovic M, **Barac A**, Petkovic A, Vojvodic N, Odalovic S, Andric Z, Miskovic R, Jovanovic D, Dimic-Janjic S, Dragasevic S, Raskovic S, Stjepanovic MI. Large-Vessel Giant Cell Arteritis following COVID-19-What Can HLA Typing Reveal? Diagnostics (Basel). 2023; 13(3):484. **M21; IF: 3.99.**
25. Deligios M, Mazzarello V, Fiamma M, **Barac A**, Diana L, Ferrari M, Murgia M, Paglietti B, Rubino S. Seasonal Variation in Fungi in Beach Sand in Summertime: Stintino (Italy). Int J Environ Res Public Health. 2023; 20(23):7134. **M21; IF: 4.61.**
26. Folic MM, **Barac A**, Ugrinovic AB, Jotic AD, Trivic AS, Milovanovic JP, Borozan NN, Peric AR, Stevanovic G, Krejovic-Trivic SB, Cvorovic L, Stojkovic GM. Effectiveness of the Treatment of Rhinogenic Headache Caused by Intranasal Contact. Ear Nose Throat J. 2023; 102(9):605-610. **M23; IF: 1.67.**
27. Milošević I, **Barać A**, Jovanović J, Vujović A, Stevanović G, Todorović N, Milošević B. A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia. Trans R Soc Trop Med Hyg. 2023; 117(9):668-672. **M22; IF: 2.46.**
28. Mohammadi Esfanjani S, Aghebati Maleki L, Nami S, Ebrahimi M, Baghbanzadeh A, Perez-Cordon G, Rodrigues Oliveira SM, De Lourdes Pereira M, **Barać A**, Ahmadpour E, Micić J. Induction of TLR5, IRAK1, and NF-κB expression by Trichomonas vaginalis in cervical cancer cell (HeLa) and normal human vaginal epithelial cell (HVECs) lines. J Infect Dev Ctries. 2023; 17(8):1160-1167. **M23; IF: 2.55.**
29. Stojanovic M, **Barac A**, Miskovic R, Jovanovic D, Bolpacic J, Ljubicic J, Stevanovic G, Jovanovic S, Bogdanovic A. Myositis-specific autoantibodies in a non-traveler, patient from a non-endemic country, with Plasmodium vivax malaria. J Infect Dev Ctries. 2023; 17(10):1497-1500. **M23; IF: 2.55.**
30. Ebrahimi M, Mehdizad N, Yeganeh-Sefidan F, Safarpour H, Pagheh AS, Pouremamali A, Shiralizadeh S, Ghodrati A, Jafari S, Shahrivar F, Heidarzadeh S, Montazeri M, Yousef-Memar M, Rodrigues-Oliveira SM, de-Lourdes-Pereira M, Beloukas A, Hatam-Nahavandi K, **Barac A**, Shirvaliloo M, Ahmadpour E. Systematic review and meta-analysis of the global prevalence of sexually transmitted infections in people living with HIV and associated risk factors. AIDS Rev. 2023; 26(3):105-126. **M23; IF: 2.38.**
31. Mirzohreh ST, Safarpour H, Pagheh AS, Bangoura B, **Barac A**, Ahmadpour E. Malaria prevalence in HIV-positive children, pregnant women, and adults: a systematic review and meta-analysis. Parasit Vectors. 2022; 15(1):324. **M21; IF: 4.052.**
32. Bogdanović M, Atanasijević T, Popović V, Mihailović Z, Radnić B, Petrović T, **Barać A.** Proper death certification in the time of the COVID-19 pandemic: Forensic perspective. J Infect Dev Ctries. 2022, 30;16(6):966-968. **M23; IF: 2.55.**
33. Despotović A, **Barać A**, Cucanić T, Cucanić K, Stevanović G. Antibiotic (Mis)Use in COVID-19 Patients before and after Admission to a Tertiary Hospital in Serbia. Antibiotics (Basel). 2022; 11(7):847. **M21; IF: 5.2.**
34. Dragutinović N, **Barać A**, Stevanović G, Đorđić I, Paglietti B, Micić J, Aleksić E, Stojnić J, Martinov Nestorov J. Acute hepatitis in a paediatric patient: immune-mediated drug-induced liver injury or albendazole-induced autoimmune hepatitis? J Infect Dev Ctries. 2022; 16(10):1660-1663. **M23; IF: 2.55.**
35. Bartoletti M, Azap O, **Barac A**, Bussini L, Ergonul O, Krause R, Martin-Quiros A, Paño-Pardo JR, Power N, Sibani M, Szabo BG, Tsiodras S, Zollner-Schwetz I, Rodríguez-Baño J. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. Clin Microbiol Infect. 2022; 28(12):1578-1590. **M21a; IF: 14.2.**
36. Perić A, Matković S, **Barać A**, Vukadinović T, Čvorović L, Vojvodić D. Evaluation of substance P and bradykinin levels in nasal secretions of patients with nasal polyposis with and without sensitivity to non-steroidal anti-inflammatory drugs. Laryngoscope Investig Otolaryngol. 2022; 7(4):928-934. **M23; IF: 2.545.**
37. **Barac A**, Bartoletti M, Azap O, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Rodríguez-Baño J, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Quirós AM, Zollner-Schwetz I. Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere! Clin Microbiol Infect. 2022; S1198-743X(22)00161-6. **M21a; IF: 14.2.**
38. Bracanovic D, Janovic A, Antic S, Rajkovic K, Bracanovic M, Tomic Spiric V, Dragutinovic N, Jadzic J, **Barac A**. 'CT and CT image-based texture image analysis in radiological diagnostics of allergic fungal rhinosinusitis'. Mycoses. 2022; 65(5):551-559. **M21; IF: 4.93**
39. Bouiller K, Peiffer-Smadja N, Cevik M, Last K, Antunović IA, Šterbenc A, Lopes MJ, **Barac A**, Schweitzer V, Dellière S. Role and perception of clinical microbiology and infectious diseases trainees during the COVID-19 crisis. Future Microbiol. 2022; 17:411-416. **M22; IF: 3.837**
40. Righi E, Yahav D, Akova M, Nasim A, **Barac A**. The ESCMID ethics advisory committee (EEAC): purpose and challenges. Clin Microbiol Infect. 2022; S1198-743X(22)00002-7. **M21a; IF: 14.2.**
41. Fiore V, Beretta R, De Vito A, **Barac A**, Maida I, Joeseph Kelvin DD, Piu C, Lai V, Madeddu G, Rubino S, Stevanovic G, Korica S, Babudieri S. Emerging Clinical Features of COVID-19 Related Pancreatitis: Case Reports and Review of the Literature. Front Med (Lausanne). 2022; 8:779118. **M21; IF: 5.093**
42. Van Braeckel E, Page I, Davidsen JR, Laursen CB, Agarwal R, Alastruey-Izquierdo A, **Barac A**, Cadranel J, Chakrabarti A, Cornely OA, Denning DW, Flick H, Gangneux JP, Godet C, Hennequin C, Hoenigl M, Kosmidis C, Lange C, Lamprecht B, Laurent F, Munteanu O, Oladele R, Patterson TF, Watanabe A, Salzer HJF. Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. Eur Respir J. 2022; 2102950. **M21a; IF: 33.801**
43. Bartoletti M, Azap O, **Barac A**, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Zollner-Schwetz I, Rodríguez-Baño J. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022; 28(2):222-238. **M21a; IF: 14.2.**
44. Rajabi S, Spotin A, Mahami-Oskouei M, Baradaran B, Babaie F, Azadi Y, Alizadeh P, Valadan R, **Barac A**, Ahmadpour E. Toxoplasma gondii activates NLRP12 inflammasome pathway in the BALB/c murine model. Acta Trop. 2022; 225:106202. **M21; IF: 3.112**
45. Pérez-Recio S, Pallarès N, Grijota-Camino MD, Sánchez-Montalvá A, Barcia L, Campos-Gutiérrez S, Pomar V, Rabuñal-Rey R, Balcells ME, Gazel D, Montiel N, Vicente D, Schön T, Paues J, Mareković I, Cacho-Calvo J, **Barac A**, Goletti D, García-Gasalla M, Barcala JM, Tórtola MT, Anibarro L, Suárez-Toste I, Moga E, Gude-Gonzalez MJ, Naves R, Karslıgil T, Martin-Peñaranda T, Stevanovic G, Trigo M, Rubio V, Karaoğlan İ, Bayram N, Alcaide F, Tebé C, Santin M; Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. Microbiol Spectr. 2021; 9(3):e0097221. **M21; IF: 9.043**
46. Cromwell EA…**Barac A**…Pigott DM. Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. PLoS Negl Trop Dis. 2021; 15(7):e0008824. **M21a; IF: 4.487**
47. Last K, Power NR, Dellière S, Velikov P, Šterbenc A, Antunovic IA, Lopes MJ, Schweitzer V, **Barac A**. Future developments in training. Clin Microbiol Infect. 2021; 27(11):1595-1600. **M21a; IF: 13.301**
48. Milosevic I, Russo E, Vujovic A, **Barac A**, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World J Gastroenterol. 2021; 27(33):5488-5501. **M22; IF: 5.742**
49. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih S, Alijani N, **Barac A**, Abdollahi A, Khodavaisy S. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses. 2021; 64(10):1238-1252. **M21; IF: 4.377**
50. Safarpour H, Pourhassan-Moghaddam M, Spotin A, Majdi H, **Barac A**, Yousefi M, Ahmadpour E. A novel enhanced dot blot immunoassay using colorimetric biosensor for detection of Toxoplasma gondii infection. Comp Immunol Microbiol Infect Dis. 2021; 79:101708. **M21; IF: 2.268**
51. Sprute R, Salmanton-García J, Sal E, Malaj X, Ráčil Z, Ruiz de Alegría Puig C, Falces-Romero I, **Barać A**, Desoubeaux G, Kindo AJ, Morris AJ, Pelletier R, Steinmann J, Thompson GR, Cornely OA, Seidel D, Stemler J; Invasive infections with Purpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature. J Antimicrob Chemother. 2021; 76(6):1593-1603. **M21a; IF: 5.790**
52. Rajic J, Gmizic I, Gunjak T, Milosevic V, Pantic N, Sabljic N, Mitrovic M, Djuric Stefanovic A, Lazic L, Jovanovic S, Milošević I, **Barac A**, Vidovic A. COVID-19-Associated Pulmonary Aspergillosis in Patients with Acute Leukemia: A Single-Center Study. J Fungi (Basel). 2021; 7(11):890. **M21; IF: 5.816**
53. Maraolo AE, **Barac A**, Cremer OL, Ong DSY. Editorial: Viral Infections in the Intensive Care Unit. Front Med (Lausanne). 2021; 8:716824. **M21; IF: 5.093**
54. Bogdanović M, Skadrić I, Atanasijević T, Stojković O, Popović V, Savić S, Mihailović Z, Radnić B, Aćimović T, Damjanjuk I, Despotović S, **Barać A**. Case Report: Post-mortem Histopathological and Molecular Analyses of the Very First Documented COVID-19-Related Death in Europe. Front Med (Lausanne). 2021; 8:612758. **M21; IF: 5.093**
55. Folic MM, **Barac AM**, Ugrinovic AB, Jotic AD, Trivic AS, Milovanovic JP, Borozan NN, Peric AR, Stevanovic G, Krejovic-Trivic SB, Cvorovic L, Stojkovic GM. Effectiveness of the Treatment of Rhinogenic Headache Caused by Intranasal Contact. Ear Nose Throat J. 2021: 1455613211019706. **M23; IF: 1.697**
56. Izadi A, Soleimani M, Daie Ghazvini R, Hashemi SJ, Gramishoar M, Ahmadikia K, Aminizadeh M, Ghahri M, Abedinifar Z, **Barac A**, Khodavaisy S. Clinical and mycological characteristics of keratitis caused by Colletotrichum gloeosporioides: A case report and review of literature. J Infect Dev Ctries. 2021; 15(2):301-305. **M23; IF: 2.55**
57. Brandão J, Gangneux JP, Arikan-Akdagli S, **Barac A**, Bostanaru AC, Brito S, Bull M, Çerikçioğlu N, Chapman B, Efstratiou MA, Ergin Ç, Frenkel M, Gitto A, Gonçalves CI, Guégan H, Gunde-Cimerman N, Güran M, Irinyi L, Jonikaitė E, Kataržytė M, Klingspor L, Mares M, Meijer WG, Melchers WJG, Meletiadis J, Meyer W, Nastasa V, Babič MN, Ogunc D, Ozhak B, Prigitano A, Ranque S, Rusu RO, Sabino R, Sampaio A, Silva S, Stephens JH, Tehupeiory-Kooreman M, Tortorano AM, Velegraki A, Veríssimo C, Wunderlich GC, Segal E. Mycosands: Fungal diversity and abundance in beach sand and recreational waters - Relevance to human health. Sci Total Environ. 2021; 781:146598. **M21a; IF: 7.963**
58. Alyssa N Sbarra…**Barac A**...Jonathan F Mosser. Local Burden of Disease Vaccine Coverage Collaborators. Mapping routine measles vaccination in low- and middle-income countries. Nature. 2021; 589(7842):415-419. **M21a; IF: 69.504**
59. Adzic-Vukicevic T, Petkovic A, Menkovic N, Stosic M, Bracanovic M, Korica S, **Barac A**. Impact of the bronchopulmonary sequestration on endobronchial tuberculosis: the case report and the review of literature. J Infect Dev Ctries. 2021; 15(11):1766-1769. **M23; IF: 2.55**
60. Dellière S, Peiffer-Smadja N, João-Lopes M, Cevik M, Pichon M, Bleibtreu A, Schweitzer V, Last K, Ferreira TG, Lemaignen A, **Barac A**. Aims and challenges of building national trainee networks in clinical microbiology and infectious disease disciplines. Future Microbiol. 2021; 16:687-695. **M22; IF: 3.165**
61. Santona A, Mhmoud NA, Siddig EE, Deligios M, Fiamma M, Bakhiet SM, **Barac A**, Paglietti B, Rubino S, Fahal AH. Metagenomics of black grains: new highlights in the understanding of eumycetoma. Trans R Soc Trop Med Hyg. 2021; 115(4):307-314. **M22; IF: 2.307**
62. Ahmadpour E, Safarpour H, Xiao L, Zarean M, Hatam-Nahavandi K, **Barac A**, Picot S, Rahimi MT, Rubino S, Mahami-Oskouei M, Spotin A, Nami S, Baghi HB. Cryptosporidiosis in HIV-positive patients and related risk factors: A systematic review and meta-analysis. Parasite. 2020; 27:27. **M22; IF: 3.000**
63. Perić A, Vezmar Kovačević S, **Barać A**, Perić AV, Vojvodić D. Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis. Laryngoscope Investig Otolaryngol. 2020; 6(1):25-33. **M22; IF: 2.458**
64. Pazoki H, Ziaee M, Anvari D, Rezaei F, Ahmadpour E, Haghparast-Kenari B, Saljoghi F, Biderouni FT, **Barac A**, Pagheh AS. Toxoplasma gondii infection as a potential risk for chronic liver diseases: A systematic review and meta-analysis. Microb Pathog. 2020; 149:104578. **M22; IF: 3.738**
65. Babaloo Z, Oskoei MR, Kohansal MH, **Barac A**, Ahmadpour E. Serum profile of IL-1β and IL-17 cytokines in patients with visceral leishmaniasis. Comp Immunol Microbiol Infect Dis. 2020; 69:101431. **M21; IF: 2.268**
66. Perić A, Gaćeša D, **Barać A**, Sotirović J, Perić AV. Herbal Drug EPs 7630 versus Amoxicillin in Patients with Uncomplicated Acute Bacterial Rhinosinusitis: A Randomized, Open-Label Study. Ann Otol Rhinol Laryngol. 2020; 129(10):969-976. **M22; IF: 1.547**
67. **Barac A**, Poljak M, Ong DSY. Editorial: Innovative Approaches in Diagnosis of Emerging/Re-emerging Infectious Diseases. Front Microbiol. 2020; 11:619498. **M21; IF: 5.640**
68. Laursen CB, Davidsen JR, Van Acker L, Salzer HJF, Seidel D, Cornely OA, Hoenigl M, Alastruey-Izquierdo A, Hennequin C, Godet C, **Barac A**, Flick H, Munteanu O, Van Braeckel E. CPAnet Registry-An International Chronic Pulmonary Aspergillosis Registry. J Fungi (Basel). 2020; 6(3):96. **M21; IF: 5.816**
69. Korać M, Rupnik M, Nikolić N, Jovanović M, Tošić T, Malinić J, Mitrović N, Marković M, Vujović A, Peruničić S, Bojović K, Djordjević V, **Barać A**, Milošević I. Clostridioides difficile ribotype distribution in a large teaching hospital in Serbia. Gut Pathog. 2020; 12:26. **M22; IF: 4.181**
70. Robert C Reiner Jr…**Barac A**…Simon I Hay. Local Burden of Disease Diarrhoea Collaborators. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10239):1779-1801. **M21a; IF: 79.323**
71. Perić A, Vezmar Kovačević S, **Barać A**, Perić AV, Vojvodić D. Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis. Laryngoscope Investig Otolaryngol. 2020; 6(1):25-33. **M22; IF: 2.458**
72. Lanternier F, Seidel D, Pagano L, Styczynski J, Mikulska M, Pulcini C, Maertens J, Munoz P, Garcia-Vidal C, Rijnders B, Arendrup MC, Sabino R, Verissimo C, Gaustad P, Klimko N, Arikan-Akdagli S, Arsic V, **Barac A**, Skiada A, Klingspor L, Herbrecht R, Donnelly P, Cornely OA, Lass-Flörl C, Lortholary O. Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe. Mycoses. 2020; 63(5):420-429. **M21; IF: 4.377**
73. Christopher E Troeger…**Barac A**…Robert C Reiner. GBD 2017 Diarrhoeal Disease Collaborators. Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. Lancet Infect Dis. 2020; 20(1):37-59. **M21a; IF: 71.42**
74. Aniruddha Deshpande…**Barac A**…Robert C Reiner Jr. Local Burden of Disease WaSH Collaborators. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17. Lancet Glob Health. 2020; 8(9):e1162-e1185. **M21a; IF: 38.927**
75. Milosevic B, Cevik M, Urosevic A, Nikolic N, Poluga J, Jovanovic M, Milosevic I, Micic J, Paglietti B, **Barac A**. Risk factors associated with poor clinical outcome in pyogenic spinal infections: 5-years' intensive care experience. J Infect Dev Ctries. 2020; 14(1):36-41. **M23; IF: 1.175**
76. Kirsten E Wiens…**Barac A**…Robert C Reiner Jr. Local Burden of Disease Diarrhoea Collaborators. Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17. Lancet Glob Health. 2020; 8(8):e1038-e1060. **M21a; IF: 26.763**
77. **Barac A**, Cevik M, Colovic N, Lekovic D, Stevanovic G, Micic J, Rubino S. Investigation of a healthcare-associated Candida tropicalis candidiasis cluster in a haematology unit and a systematic review of nosocomial outbreaks. Mycoses. 2020; 63(4):326-333. **M21; IF: 4.377**
78. Ahmadpour E, Foroutan-Rad M, Majidiani H, Moghaddam SM, Hatam-Nahavandi K, Hosseini SA, Rahimi MT, **Barac A**, Rubino S, Zarean M, Mathioudakis AG, Cevik M. Corrigendum to: Transfusion-Transmitted Malaria: A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2020; 7(1):ofz540. **M22; IF: 3.835**
79. Safarpour H, Cevik M, Zarean M, **Barac A**, Hatam-Nahavandi K, Rahimi MT, Bannazadeh Baghi H, Koshki TJ, Pagheh AS, Shahrivar F, Ebrahimi M, Ahmadpour E. Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV. AIDS. 2020; 34(3):469-474. **M21; IF: 4.534**
80. Adzic-Vukicevic T, Cevik M, Poluga J, Micic J, Rubino S, Paglietti B, **Barac A**. An exceptional case report of disseminated cryptococcosis in a hitherto immunocompetent patient. Rev Inst Med Trop Sao Paulo. 2020; 62:e3. **M22; IF: 1.846**
81. Hamzeh Pour S, Mahmoudi S, Masoumi S, Rezaie S, **Barac A**, Ranjbaran M, Oliya M, Mehravar F, Sasani E, Noorbakhsh F, Khodavaisy S. Aflatoxin M1 contamination level in Iranian milk and dairy products: a systematic review and meta-analysis. World Mycotoxin J. 2020; 13:11, 67-82. **M22; IF: 3.108**
82. Puca E, Čivljak R, Arapović J, Popescu C, Christova I, Raka L, Cana F, Miranović V, Karageorgopoulos D, Baš D, Paglietti B, **Barać A**. Short epidemiological overview of the current situation on COVID-19 pandemic in Southeast European (SEE) countries. J Infect Dev Ctries. 2020; 14(5):433-437. **M23; IF: 1.175**
83. Salehi Z, Fatahi N, Taran M, Izadi A, Badali H, Hashemi SJ, Rezaie S, Daie Ghazvini R, Ghaffari M, Aala F, **Barac A**, Khodavaisy S. Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis. J Mycol Med. 2020; 30(2):100935. **M23; IF: 2.391**
84. Christopher E Troeger…**Barac A**…Robert C Reiner. GBD 2017 Lower Respiratory Infections Collaborators. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2020; 20(1):60-79. **M21a; IF: 71.42**
85. Meštrović T, Ljubin-Sternak S, Božičević I, Drenjančević D, **Barać A**, Kozina G, Neuberg M, Vraneš J. Human Papillomavirus (HPV) Prevalence, Temporal Dynamics and Association with Abnormal Cervical Cytology Findings in Women from Croatia: Is there a Compounding Effect of Low-Risk/High-Risk HPV Co-Infection? Clin Lab. 2020; 66(12). **M23; IF: 1.138**
86. Perić A, Kovačević SV, **Barać A**, Gaćeša D, Perić AV, Jožin SM. Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. Acta Otolaryngol. 2019; 139(6):529-535. **M23; IF: 1.494**
87. **Barac A**, Kosmidis C, Alastruey-Izquierdo A, Salzer HJF. Chronic pulmonary aspergillosis update: A year in review. Med Mycol. 2019; 57(2):S104-S109. **M21a; IF: 4.076**
88. Meštrović T, Wilson J, Ljubin-Sternak S, Sviben M, Bedenić B, **Barać A**, Neuberg M, Drenjančević D, Ribić R, Kozina G. A 'pathogenic needle' in a 'commensal haystack': Genetic virulence signatures of Corynebacterium glucuronolyticum that may drive its infectious propensity for the male urogenital system. Med Hypotheses. 2019; 126:38-41. **M23; IF: 1.538**
89. **Barac A**, Knerer B, Neuchrist C, Sacu GS, Peric A, Mueller CA, Erovic BM. Long-term improvement of clinical symptoms after endoscopic sinus surgery in patients suffered from endocrine ophthalmopathy and orbital complications of rhinosinusitis. Acta Otolaryngol. 2019; 139(10):876-880. **M23; IF: 1.494**
90. Milosevic I, Vujovic A, **Barac A**, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019; 20(2):395. **M21; IF: 5.924**
91. Reiner RC Jr…**Barac A**…Kassebaum NJ. GBD 2017 Child and Adolescent Health Collaborators. Diseases, Injuries, and Risk Factors in Child and Adolescent Health, 1990 to 2017: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2017 Study. JAMA Pediatr. 2019; 173(6):e190337. **M21a; IF: 16.193**
92. Salmanton-García J, Seidel D, Koehler P, Mellinghoff SC, Herbrecht R, Klimko N, Ráčil Z, Falces-Romero I, Ingram P, Benítez-Peñuela MÁ, Rodríguez JY, Desoubeaux G, **Barać A**, García-Vidal C, Hoenigl M, Mehta SR, Cheng MP, Klyasova G, Heinz WJ, Iqbal N, Krause R, Ostermann H, Penack O, Schalk E, Sheppard DC, Willinger B, Wisplinghoff H, Vehreschild JJ, Cornely OA, Vehreschild MJGT. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations. J Antimicrob Chemother. 2019; 74(11):3315-3327. **M21a; IF: 5.790**
93. Nasri E, Fakhim H, **Barac A**, Yousefi S, Aghazade K, Boljevic D, Mardani M. Nocardia farcinica meningitis in a patient with high-grade astrocytoma. J Infect Dev Ctries. 2019 Sep 30;13(9):854-857. **M23; IF: 1.175**
94. Poluga J, **Barac A**, Katanic N, Rubino S, Milosevic B, Urosevic A, Mitrovic N, Kelic I, Micic J, Stevanovic G. Tick-borne encephalitis in Serbia: A case series. J Infect Dev Ctries. 2019; 13(6):510-515. **M23; IF: 1.175**
95. **Barac A**, Karimzadeh-Esfahani H, Pourostadi M, Rahimi MT, Ahmadpour E, Rashedi J, Mahdavipoor B, Kafil HS, Spotin A, Abate KH, Mathioudakis AG, Asgharzadeh M. Laboratory Cross-Contamination of Mycobacterium tuberculosis: A Systematic Review and Meta-analysis. Lung. 2019; 197(5):651-661. **M23; IF: 2.584**
96. Jeffrey D Stanaway…Barac A…Simon I Hay. GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019; 19(4):369-381. **M21a; IF: 71.42**
97. Ong DSY, Zapf TC, Cevik M, Palacios-Baena ZR, **Barać A**, Cimen C, Maraolo AE, Rönnberg C, Cambau E, Poljak M. Current mentorship practices in the training of the next generation of clinical microbiology and infectious disease specialists: an international cross-sectional survey. Eur J Clin Microbiol Infect Dis. 2019; 38(4):659-665. **M22; IF: 3.267**
98. Burstein R…**Barac A**…Hay SI. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature. 2019; 574(7778):353-358. **M21a; IF: 49.962**
99. Ahmadpour E, Pishkarie-Asl R, Spotin A, Samadi Kafil H, Didarlu H, Azadi Y, **Barac A**. Sero-molecular evaluation of Toxoplasma gondii infection among HIV-positive patients. Trans R Soc Trop Med Hyg. 2019; 113(12):771-775. **M22; IF: 2.307**
100. Murgia M, Fiamma M, Barac A, Deligios M, Mazzarello V, Paglietti B, Cappuccinelli P, Al-Qahtani A, Squartini A, Rubino S, Al-Ahdal MN. Biodiversity of fungi in hot desert sands. Microbiologyopen. 2019; 8(1):e00595. **M22; IF: 3.142**
101. Barabadi H, Alizadeh Z, Rahimi MT, **Barac A**, Maraolo AE, Robertson LJ, Masjedi A, Shahrivar F, Ahmadpour E. Nanobiotechnology as an emerging approach to combat malaria: A systematic review. Nanomedicine. 2019; 18:221-233. **M21a; IF: 6.458**
102. Trivić A, Cevik M, Folić M, Krejovic-Trivić S, Rubino S, Micić J, Stevanović G, Milovanović J, Jotić A, **Barać A**. Management of Orbital Complications of Acute Rhinosinusitis in Pediatric Patients: A 15-Year Single-Center Experience. Pediatr Infect Dis J. 2019; 38(10):994-998. **M22; IF: 2.31**
103. Mahmoudi S, Badali H, Rezaie S, Azarnezhad A, **Barac A**, Kord M, Ahmadikia K, Aala F, Ali Askari F, Meis JF, Khodavaisy S. A simple and low cost tetra-primer ARMS-PCR method for detection triazole-resistant Aspergillus fumigatus. Mol Biol Rep. 2019; 46(4):4537-4543. **M23; IF: 2.316**
104. Ahmadpour E, Zargami E, Mahami-Oskouei M, Spotin A, Shahbazi A, Kafil HS, Rajabi S, Alizadeh P, Azadi Y, Bahaj R, Shahrivar F, **Barac A**. Diagnosis of *Toxoplasma gondii* infection in pregnant women using automated chemiluminescence and quantitative real time PCR. Asian Pac J Trop Med 2019; 12:26-31. **M22; IF: 1.940**
105. Modiri M, Khodavaisy S, **Barac A**, Akbari Dana M, Nazemi L, Aala F, Salehi M, Rezaie S. Comparison of biofilm-producing ability of clinical isolates of Candida parapsilosis species complex. J Mycol Med. 2019; 29(2):140-146. **M23; IF: 2.391**
106. Nazemi L, Hashemi SJ, Daie Ghazvini R, Saeedi M, Khodavaisy S, **Barac A**, Modiri M, Akbari Dana M, Zare Shahrabadi Z, Rezaie S. Investigation of cgrA and cyp51A gene alternations in Aspergillus fumigatus strains exposed to kombucha fermented tea. Med Mycol. 2019; 5(3):36-42. **M21a; IF: 4.076**
107. Tahvi D Frank…**Barac A**…Christopher J L Murray. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019; 6(12):e831-e859. **M21a; IF: 14.753**
108. Boljevic D, **Barac A**, Vukovic P, Kojic D, Bojic M, Micic J, Rubino S, Paglietti B, Nikolic A. A rare case of pacemaker lead endocarditis successfully treated with open heart surgery. J Infect Dev Ctries. 2019; 13(11):1068-1071. **M23; IF: 1.175**
109. **Barac A**, Stevanovic G, Pekmezovic M, Rakocevic Z, Stosovic R, Erovic B, Tomic Spiric V. Study toward resolving the controversy over the definition of allergic fungal rhinosinusitis. Med Mycol. 2018; 56(2):162-171. **M21a; IF: 4.076**
110. Popovic N, Korac M, Nesic Z, Milosevic B, Urosevic A, Jevtovic D, Mitrovic N, Markovic A, Jordovic J, Katanic N, **Barac A**, Milosevic I. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study. Eur J Clin Microbiol Infect Dis. 2018; 37(4):745-754. **M22; IF: 3.267**
111. Hmwe Hmwe Kyu…**Barac A**…Christopher J L Murray. GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis. 2018; 18(12):1329-1349. **M21a; IF: 27.516**
112. Lars Jacob Stovner…**Barac A**…Christopher J L Murray. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11):954-976. **M21a; IF: 44.182**
113. Christopher E Troeger…**Barac A**…Robert C Reiner. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2018; 7(1):69-89. **M21a; IF: 30.700**
114. Cowan AJ, Allen C, **Barac A**, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, Jakovljevic M, Khader Y, Linn S, Lad D, Mantovani L, Nong VM, Mokdad A, Naghavi M, Postma M, Roshandel G, Shackelford K, Sisay M, Nguyen CT, Tran TT, Xuan BT, Ukwaja KN, Vollset SE, Weiderpass E, Libby EN, Fitzmaurice C. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018; 4(9):1221-1227. **M21a; IF: 31.777**
115. Stevanovic G, Lavadinovic L, Filipovic Vignjevic S, Holt R, Ilic K, Berlanda Scorza F, Sparrow E, Stoiljkovic V, Torelli G, Madenwald T, Socquet M, **Barac A**, Ilieva-Borisova Y, Pelemis M, Flores J. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults. Hum Vaccin Immunother. 2018; 14(3):579-586. **M22; IF: 3.452**
116. Milošević I, Karić U, Pešić-Pavlović I, Stevanović G, **Barać A**, Smiljanić M, Arsenović A, Stevanović O, Đonin-Nenezić M, Brmbolić B. Successful treatment of chronic hepatitis C in a hemodialysis. J Infect Dev Ctries. 2018; 12(2):142-145. **M23; IF: 1.175**
117. Joseph Raymond Zunt…**Barac A**…Christopher J L Murray. GBD 2016 Meningitis Collaborators. Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(12):1061-1082. **M21a; IF: 44.182**
118. Karic U, Pesic-Pavlovic I, Stevanovic G, Korac M, Nikolic N, Radovanovic-Spurnic A, **Barac A**, Mitrovic N, Markovic A, Markovic M, Petkovic A, Ostojic I, Perunicic S, Kekic N, Glidzic M, Djonin-Nenezic M, Brmbolic B, Milosevic I. FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country's perspective in DAA era. J Infect Dev Ctries. 2018; 12(3):178-182. **M23; IF: 1.175**
119. Surda P, **Barac A**, Mobaraki Deghani P, Jacques T, Langdon C, Pimentel J, Mathioudakis A, Tomazic P.V. Training in ENT; a comprehensive review of existing evidence. Rhinology. 2018; 1:77-84. **M21a; IF: 3.681**
120. Galeh TM, Spotin A, Mahami-Oskouei M, Carmena D, Rahimi MT, **Barac A**, Ghoyounchi R, Berahmat R, Ahmadpour E. The seroprevalence rate and population genetic structure of human cystic echinococcosis in the Middle East: A systematic review and meta-analysis. Int J Surg. 2018; 51:39-48. **M21a; IF: 6.071**
121. **Barac A**, Ong DSY, Jovancevic L, Peric A, Surda P, Tomic Spiric V, Rubino S. Fungi-Induced Upper and Lower Respiratory Tract Allergic Diseases: One Entity. Front Microbiol. 2018; 9:583. **M21; IF: 5.640**
122. Basaric D, Lekic N, Djordjevic V, Ceranic M, **Barac A**, Stevanovic G, Milosevic I. Actinomycotic hepatic abscess in woman with longstanding intrauterine contraceptive device. J Infect Dev Ctries. 2018; 12(8):683-686. **M23; IF: 1.175**
123. Azadi Y, Ahmadpour E, Hamishehkar H, Daryani A, Spotin A, Mahami-Oskouei M, **Barac A**, Rajabi S, Alizadeh P, Montazeri M. Quantification of Toxoplasma gondii in the tissues of BALB/c mice after immunization with nanoliposomal excretory-secretory antigens using Real-Time PCR. Comparative immunology microbiology and infectious diseases. 2018; 59;52-56. **M21; IF: 2.268**
124. Jeffrey D Stanaway…**Barac A**…Christopher J L Murray. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(1923-1994). **M21a; IF: 79.323**
125. Joseph L Dieleman…**Barac A**…Christopher J L Murray. Global Burden of Disease Health Financing Collaborator Network. Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995-2015. Lancet. 2018; 391(10132):1799-1829. **M21a; IF: 79.323**
126. Ubai Alsharif…**Barac A**…Christina Fitzmaurice. GBD 2015 Eastern Mediterranean Region Cancer Collaborators. Burden of cancer in the Eastern Mediterranean Region, 2005-2015: findings from the Global Burden of Disease 2015 Study. Int J Public Health. 2018; 63(1):151-164. **M21; IF: 3.380**
127. Ibrahim Khalil…**Barac A**…Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Maternal Mortality Collaborators. Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):47-61. **M21; IF: 3.380**
128. Sare Safi...**Barac A**...Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Vision Loss Collaborators. Burden of vision loss in the Eastern Mediterranean region, 1990-2015: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):199-210. **M21; IF: 3.380**
129. Arash Tehrani-Banihashemi…**Barac A**…Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Cardiovascular Disease Collaborators. Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990-2015: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):137-149. **M21; IF: 3.380**
130. Joseph L Dieleman…**Barac A**…Christopher J L Murray. Global Burden of Disease Health Financing Collaborator Network. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016-40. Lancet. 2018; 391(10132):1783-1798. **M21a; IF: 79.323**
131. Maziar Moradi-Lakeh...**Barac A**...Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Lower Respiratory Infections Collaborators. Burden of lower respiratory infections in the Eastern Mediterranean Region between 1990 and 2015: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):97-108. **M21; IF: 3.380**
132. Raghid Charara…**Barac A**…Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Mental Health Collaborators. The burden of mental disorders in the Eastern Mediterranean region, 1990-2015: findings from the global burden of disease 2015 study. Int J Public Health. 2018; 63(1):25-37. **M21; IF: 3.380**
133. Charbel El Bcheraoui…**Barac A**…Ali H Mokdad. GBD 2015 Eastern Mediterranean Region HIV/AIDS Collaborators. Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990-2015: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):123-136. **M21; IF: 3.380**
134. Maziar Moradi-Lakeh...**Barac A**...Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Diabetes and Chronic Kidney Disease Collaborators. Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):177-186. **M21; IF: 3.380**
135. Adzic-Vukicevic T, **Barac A**, Blanka-Protic A, Laban-Lazovic M, Lukovic B, Skodric-Trifunovic V, Rubino S. Clinical features of infection caused by non-tuberculous mycobacteria: 7 years' experience. Infection. 2018; 46(3):357-363. **M22; IF: 3.553**
136. Azadi Y, Ahmadpour E, Hamishehkar H, Daryani A, Spotin A, Mahami-Oskouei M, **Barac A**, Rajabi S, Alizadeh P, Montazeri M. Quantification of Toxoplasma gondii in the tissues of BALB/c mice after immunization with nanoliposomal excretory-secretory antigens using Real-Time PCR. Comp Immunol Microbiol Infect Dis. 2018; 59:52-56. **M21; IF: 2.268**
137. Ibrahim Khalil…**Barac A**…Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Neonatal, Infant, and under-5 Mortality Collaborators. Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):63-77. **M21; IF: 3.380**
138. Spencer L James…**Barac A**…Christopher J L Murray. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. **M21a; IF: 79.323**
139. Feigin VL…**Barac A**…Roth GA. GBD 2016 Lifetime Risk of Stroke Collaborators. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. N Engl J Med. 2018; 379(25):2429-2437. **M21a; IF: 91.253**
140. Hmwe Hmwe Kyu…**Barac A**…Christopher J L Murray. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1859-1922. **M21a; IF: 79.323**
141. Christopher Troeger…**Barac A**…Robert C Reiner Jr. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018; 18(11):1191-1210. **M21a; IF: 27.516**
142. Christopher Troeger…**Barac A**...Robert C Reiner Jr. GBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018; 18(11):1211-1228. **M21a; IF: 27.516**
143. Daniel Dicker…**Barac A**…Christopher J L Murray. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1684-1735. **M21a; IF: 79.323**
144. Rafael Lozano…**Barac A**…Christopher J L Murray. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):2091-2138. **M21a; IF: 79.323**
145. Roth GA…**Barac A**…Murray CJL. Global Burden of Cardiovascular Diseases Collaboration. The Burden of Cardiovascular Diseases Among US States, 1990-2016. JAMA Cardiol. 2018; 3(5):375-389. **M21a; IF: 14.676**
146. Hmwe H Kyu…**Barac A**…Christopher Jl Murray. GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018; 18(3):261-284. **M21a; IF: 27.516**
147. **Barac A**, Donadu M, Usai D, Spiric VT, Mazzarello V, Zanetti S, Aleksic E, Stevanovic G, Nikolic N, Rubino S. Antifungal activity of Myrtus communis against Malassezia sp. isolated from the skin of patients with pityriasis versicolor. Infection. 2018; 46(2):253-257. **M22; IF: 3.553**
148. Mitrovic N, Delic D, Markovic Denic L, Nikolic N, Bojovic K, Simonovic Babic J, Brmbolic B, Milosevic I, Katanic N, **Barac A**. The prevalence and the risk factors for hepatitis C virus infection in Serbia. J Infect Dev Ctries. 2018; 12(3):171-177. **M23; IF: 1.175**
149. Adzic-Vukicevic T, **Barac A**, Blanka-Protic A, Popovic S, Uskokovic-Stefanovic Z, Stojsic J, Ilic AD. Endotracheal stent increased survival length in patients with invasive thymic adenocarcinoma. J Res Med Sci. 2018; 23:30. **M23; IF: 1.852**
150. Adzic-Vukicevic T, Stojsic J, **Barac A**, Protic AB, Andrejevic S, Raljevic S. The rare case report of interstitial lung disease with normal serum level of IgG4 developed six years after treatment of autoimmune pancreatitis. Sarcoidosis Vasc Diffuse Lung Dis. 2017; 34(4):377-380. **M23; IF: 1.575**
151. Afshin A…**Barac A**…Murray CJL. GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1):13-27. M**21a; IF: 91.253**
152. **Barac A**, Mitulovic G, Hallström S, Zehetmayer S, Grasl MC, Erovic BM. Impact of combined treatment with nimesulide and cisplatin on oral carcinoma cells. Onco Targets Ther. 2017; 10:3607-3616. **M23; IF: 4.147**
153. Adzic-Vukicevic T, **Barac A**, Ilic AD, Jankovic R, Hadzi-Djokic J, Pesut D. First reported case of fulminant TB with progression of infection from lungs to the genitourinary region. Rev Inst Med Trop Sao Paulo. 2017; 59:e20. **M22; IF: 1.846**
154. Marissa B Reitsma...**Barac A**…Emmanuela Gakidou. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017; 389(10082):1885-1906. **M21a; IF: 79.323**
155. Kostić T, Momčilović S, Perišić ZD, Apostolović SR, Cvetković J, Jovanović A, **Barać A**, Šalinger-Martinović S, Tasić-Otašević S. Manifestations of Lyme carditis. Int J Cardiol. 2017; 232:24-32. **M21; IF: 76.189**
156. Ryan M Barber…**Barac A**…Christopher J L Murray. GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet. 2017; 390(10091):231-266. **M21a; IF: 79.323**
157. Roth GA…**Barac A**…Murray C. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1-25. **M21a; IF: 20.589**
158. Christopher Troeger…**Barac A**…Ali H Mokdad. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017; 17(9):909-948. **M21a; IF: 27.516**
159. Kassebaum N…**Barac A**…Vos T. Global Burden of Disease Child and Adolescent Health Collaboration. Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. JAMA Pediatr. 2017; 171(6):573-592. **M21a; IF: 19.193**
160. Joseph L Dieleman…**Barac A**…Christopher J L Murray. Global Burden of Disease Health Financing Collaborator Network. Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet. 2017; 389(10083):2005-2030. **M21a; IF: 79.323**
161. Joseph Dieleman…**Barac A**…Christopher J L Murray. Global Burden of Disease Health Financing Collaborator Network. Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet. 2017; 389(10083):1981-2004. **M21a; IF: 79.323**
162. Vukicevic TA, Dudvarski-Ilic A, Zugic V, Stevanovic G, Rubino S, **Barac A**. Subacute invasive pulmonary aspergillosis as a rare cause of pneumothorax in immunocompetent patient: brief report. Infection. 2017; 45(3):377-380. **M22; IF: 3.040**
163. Marissa B Reitsma…**Barac A**…Emmanuela Gakidou. GBD 2015 Tobacco Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2017; 390(10100):1211-1259. **M21a; IF: 79.323**
164. **Barac A**, Vukicevic TA, Ilic AD, Rubino S, Zugic V, Stevanovic G. Complications of chronic necrotizing pulmonary aspergillosis: review of published case reports. Rev Inst Med Trop Sao Paulo. 2017; 59:e19. **M22; IF: 1.846**
165. Christopher Troeger…**Barac A**…Ali H Mokdad. GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017; 17(11):1133-1161. **M21a; IF: 27.516**
166. Howard P, Huttner B, Beovic B, Beraud G, Kofteridis DP, Pano Pardo J, Schouten J, Pulcini C; ESGAP Indicators Working Group (Angioni G, Arvaniti K, **Barac A**, Bolla C, Calbo E, Dyar OJ, Fantoni M, Fjeld H, Keuleyan E, Kumar S, Harhxi A, Jenkins D, Maurer F, Pagani L, Pereira NMR, Rodrigues-Bano J, Skodvin B, Tängden T, Vitrat V, Vlahovic-Palcevski V, Zarb P). ESGAP inventory of target indicators assessing antibiotic prescriptions: a cross-sectional survey. J Antimicrob Chemother. 2017; 72(10):2910-2914. **M21a; IF: 5.790**
167. Akinyemiju T…**Barac A**…Fitzmaurice C. Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. **M21a; IF: 31.777**
168. Emmanuela Gakidou…**Barac A**…Christopher J L Murray. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1345-1422. **M21a; IF: 79.323**
169. Simon I Hay…**Barac A**…Christopher J L Murray. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1260-1344. **M21a; IF: 79.323**
170. Nancy Fullman…**Barac A**…Christopher J L Murray. GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1423-1459. **M21a; IF: 79.323**
171. Haidong Wang…**Barac A**…Christopher J L Murray. GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1084-1150. **M21a; IF: 79.323**
172. Mohsen Naghavi…**Barac A**…Christopher J L Murray. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1151-1210. **M21a; IF: 79.323**
173. Joan B Soriano…**Barac A**…Theo Vos. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017; 5(9):691-706. **M21a; IF: 30.700**
174. Valery L Feigin…**Barac A**…Theo Vos. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; 16(11):877-897. **M21a; IF: 44.182**
175. Mohammad H Forouzanfar…**Barac A**…Christopher J L Murray. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 Risk Factors Collaborators. Lancet. 2016; 388(10053):1659-1724. **M21a; IF: 79.323**
176. Nicholas J Kassebaum…**Barac A**…Christopher J L Murray. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 DALYs and HALE Collaborators. Lancet. 2016; 388(10053):1603-1658. **M21a; IF: 79.323**
177. Fitzmaurice C…**Barac A**…Naghavi M. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017; 3(4):524-548. **M21a; IF: 31.777**
178. Theo Vos…**Barac A**…Christopher J L Murray. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2016; 388(10053):1545-1602. **M21a; IF: 79.323**
179. Haidong Wang…**Barac A**…Christopher J L Murray. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 Mortality and Causes of Death Collaborators. Lancet. 2016; 388(10053):1459-1544. **M21a; IF: 79.323**
180. Haidong Wang…**Barac A**…Christopher J L Murray. GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: The Global Burden of Disease Study 2015. Lancet HIV. 2016; 3(8):e361-e387. **M21a; IF: 79.323**
181. Maziar Moradi-Lakeh...**Barac A**...Ali H Mokdad. GBD 2015 Eastern Mediterranean Region Intentional Injuries Collaborators. Intentional injuries in the Eastern Mediterranean Region, 1990-2015: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018; 63(1):39-46. **M21; IF: 3.380**
182. Čolović N, Arsić-Arsenijević V, **Barać A**, Suvajdžić N, Leković D, Tomin D. Mucormycosis of the paranasal sinuses in a patient with acute myeloid leukemia. Srp Arh Celok Lek. 2016; 144(11-12):657-60. **M23; IF: 0.228**
183. Haidong Wang…**Barac A**…Christopher J L Murray. GBD 2015 Child Mortality Collaborators. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1725-1774. **M21a; IF: 79.323**
184. Pekmezovic M, Aleksic I, **Barac A**, Arsic-Arsenijevic V, Vasiljevic B, Nikodinovic-Runic J, Senerovic L. Prevention of polymicrobial biofilms composed of Pseudomonas aeruginosa and pathogenic fungi by essential oils from selected Citrus species. Pathog Dis. 2016; 74(8):ftw102. **M22; IF: 3.166**
185. Vesna TS, Denisa D, Slavenka J, Lidija B, **Aleksandra B**, Jasna B, Vojislav D, Aleksandra PP, Aleksandra A, Mirjana B. Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. Iran J Allergy Asthma Immunol. 2016; 15(2):112-21. **M23; IF: 1.464**
186. Khalil I…**Barac A**…Mokdad AH. Burden of Diarrhea in the Eastern Mediterranean Region, 1990-2013: Findings from the Global Burden of Disease Study 2013. Am J Trop Med Hyg. 2016; 95(6):1319-1329. **M21; IF: 2.564**
187. Lim S…**Barac A**…Murray CJL. GBD 2015 SDG Collaborators.Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. GBD 2015 SDG Collaborators. Lancet. 2016; 388(10053):1813-1850. **M21a; IF: 79.323**
188. Dudvarski Ilic A, Zugic V, Zvezdin B, Kopitovic I, Cekerevac I, Cupurdija V, Perhoc N, Veljkovic V, **Barac A**. Influence of inhaler technique on asthma and COPD control: a multicenter experience. Int J Chron Obstruct Pulmon Dis. 2016; 11:2509-2517. **M21; IF: 3.046**
189. Otašević S, **Barac A**, Pekmezovic M, Tasic S, Ignjatović A, Momčilović S, Stojanović P, Arsic Arsenijevic V, Hay R. The prevalence of Candida onychomycosis in Southeastern Serbia from 2011 to 2015. Mycoses. 2016; 59(3):167-72. **M21; IF: 4.377**
190. Nicholas J Kassebaum…**Barac A**…Christopher J L Murray. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 Maternal Mortality Collaborators. Lancet. 2016; 388(10053):1775-1812. **M21a; IF: 79.323**
191. **Barac A**, Pekmezovic M, Spiric VT, Trivic A, Marinkovic J, Pekic S, Arsenijevic VA. Chronic rhinosinusitis: association of recalcitrant nasal polyposis and fungal finding in polyp's single-cell suspension. Eur Arch Otorhinolaryngol. 2015; 272(12):3727-34. **M21; IF: 1.660**
192. Pekmezovic M, Rajkovic K, **Barac A**, Senerović l, Arsic Arsenijevic V. Development of kinetic model for testing antifungal effect of Thymus vulgaris L. and Cinnamomum cassia L. essential oils on Aspergillus flavus spores and application for optimization of synergistic effect. Biochemical Engineering Journal. 2015; 99:131-137. **M21; IF: 3.226**
193. **Barac A**, Pekmezovic M, Milobratovic D, Otasevic-Tasic S, Radunovic M, Arsic Arsenijevic V. Presence, species distribution, and density of Malassezia yeast in patients with seborrhoeic dermatitis - a community-based case-control study and review of literature. Mycoses. 2015; 58(2):69-75. **M21; IF: 4.377**
194. Rajkovic K, Pekmezovic M, **Barac A**, Nikodinovic-Runic J, Arsic Arsenijevic V. Inhibitory effect of thyme and cinnamon essential oils on Aspergillus flavus: Optimization and activity prediction model development. Industrial Crops and Products. 2015; 65:7-13. **M21a; IF: 3.449**
195. Arsic Arsenijevic VS, Pekmezovic MG, Rajkovic KM, Vekic BP, **Barac AM**, Tasic-Otasevic S, Petkovic LDj. In vitro protease inhibition and cytotoxicity of Aspergillus fumigatus biomolecules secreted under long-term aerated conditions. Int J Med Sci. 2014; 11(11):1133-9. **M21; IF: 2.399**
196. Arsic-Arsenijevic V, **Barac A**, Pekmezovic M, Stosovic R, Penđer I. Alergijski fungalni sinusitis-novi aspekti kliničkih odlika, laboratorijske dijagnoze I lečenja. Srp Arh Celok Lek. 2013; 141(9-10):698-704. **M23; IF: 0.228**
197. Trpković A, Pekmezović M, **Barać A**, Crnčević Radović L, Arsić Arsenijević V. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia. J Mycol Med. 2012; 22(3):243-248. **M23; IF: 2.391**
198. Arsic Arsenijevic V, Petkovic Lj, Džamić A, Čolović I, **Barać** A, Ihan A. A murine model for study of anticryptococcal activity mediated by cytotoxic immune cells: Role in immunization and human vaccine strategies. Acta veterinaria. 2011; 61(2-3):109-118. **M23; IF: 0.800**

**CEO RAD U ČASOPISU KOJI NIJE UKLJUČEN U GORE POMENUTE BAZE PODATAKA**

1. Ananth S, Adeoti AO, Ray A, et al. (...**Barac A**...) AMR-Lung Clinical Research Collaboration. Healthcare worker views on antimicrobial resistance in chronic respiratory disease. Antimicrob Resist Infect Control. 2025; 14(1):1. **M21; IF: 4.8, ½IF: 2.4**
2. Gangneux JP, Brandao J, Segal E, et al. (...**Barac A**...) ECMM/ISHAM MYCOSANDS study group. Knowledge and regulation on fungal contamination of sand and water: Progress report and perspectives. Med Mycol. 2024; 62(2):137. **M21a; IF: 3.75; ½IF: 1.875.**
3. Salmanton-García J, Falci DR, Cornely OA, Pasqualotto AC, et al. (...**Barac A**...) IFI Diagnostic and Treatment Capacity Teams Brazil and Europe. Elevating fungal care: bridging Brazil's healthcare practices to global standards. Microbiol Spectr. 2025; 13(4):e0211224. **M22; IF: 4.2; ½IF: 2.1.**
4. **Aleksandra Barac**. A global focus on fungal infections. Lancet Infect Dis. 2024 Mar; 24(3):236. **M21a; IF: 71.42; ½IF: 35.71.**
5. Lahmer T, Salmanton-García J, Marchesi F, et al. (...**Barac A...**) EPICOVIDEHA registry. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024; 52(3):1125-1141. **M21; IF: 7.55; ½IF: 3.775**
6. Salmanton-García J, Marchesi F, Farina F, et al. (...**Barac A...**) EPICOVIDEHA registry. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024; 71:102553. **M21a; IF: 17.033; ½IF: 8.52**
7. Mathioudakis A, Fally M, Hansel J, et al. (...**Barac A**...) Pneumonia Outcomes Group. Pneumonia Outcomes Group. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments. J Clin Epidemiol. 2023; 164:88-95. **M21a; IF: 7.407; ½IF: 3.9.**
8. Hoenigl M, Salmanton-García J, Egger M, et al. (...**Barac A...**) ECMM Candida III Study Group. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis. 2023; 23(6):751-761. **M21a; IF: 71.42; ½IF: 35.71.**
9. Rossi G, Salmanton-García J, Cattaneo C, et al. (...**Barac A...**) Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings. Int J Infect Dis. 2023; 137:98-110. **M21; IF: 12.07; ½IF: 6.035**
10. Ikuta K, Swetschinski L, Aguilar G, et al. (...**Barac A...**) GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022; 400(10369):2221-2248. **M21a; IF: 98.4; ½IF: 49.2.**
11. Bartoletti M, Azap O, **Barac A**, Bussini L, Ergonul O, Krause R, Martín-Quirós A, Paño-Pardo JR, Power N, Sibani M, Szabo B, Tsiodras S, Zollner-Schwetz I, Rodriguez-Baño J; ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply. Clin Microbiol Infect. 2022; 28(4):617-618. **M21a; IF= 14.2; ½IF= 7.1.**
12. Pagano L, Salmanton-García J, Marchesi F, et al. (...Barac A...); EPICOVIDEHA working group. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021; 14(1):168. **M21a; IF: 23.168; ½IF: 11.6.**
13. Maraolo AE, Ong DSY, Cimen C, et al. (…**Barac A**…) ESGAP-EUCIC-TAE Working Group on AMS/IPC mapping in Europe. Organization and training at national level of antimicrobial stewardship and infection control activities in Europe: an ESCMID cross-sectional survey. Eur J Clin Microbiol Infect Dis. 2019; 38(11):2061-2068. **M22; IF: 3.267; ½IF:** **1.63.**
14. Saydam FN, Erdem H, Ankarali H, et al. (…**Barac A**…). Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia. Travel Med Infect Dis. 2021; 44:102174. **M21a; IF: 6.211; ½IF: 3.11**
15. Salmanton-García J, Koehler P, Kindo A, et al. (…**Barac A**…). Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope-Global Registry for Emerging Fungal Infections. J Infect. 2020; 81(5):802-815. **M21; IF: 6.072; ½IF: 3.036.**
16. Medina N, Soto-Debrán JC, Seidel D, et al. (…**Barac A**…). MixInYeast: A Multicenter Study on Mixed Yeast Infections. J Fungi (Basel). 2020; 7(1):13. **M21; IF: 5.816; ½IF: 2.91**
17. Peric A, Gacesa D, **Barac A**, Peric A. A Herbal Formula in the Therapy of Acute Postviral Rhinosinusitis. Turk Arch Otorhinolaryngol. 2021; 59(1):33-42.
18. Perić A, Vezmar Kovačević S, **Barać A**, Gaćeša D, Perić AV, Vojvodić D. Effects of Pelargonium sidoides extract on chemokine levels in nasal secretions of patients with non-purulent acute rhinosinusitis. J Drug Assess. 2020; 9(1):145-150.
19. Meštrović T, Cevik M, Pinto TCA, **Barać A**, Servín-Garcidueñas LE, Ong DSY. The Convergent Effect of International Collaboration between Young Leaders of Two Global Societies: Strengthening Microbiology Education and Training Practices Worldwide. J Microbiol Biol Educ. 2019; 20(1):20.1.27. IF
20. Arsic Arsenijevic V, Milobratovic D, **Barac A**, Vekic B, Marinkovic J, Kostic V. A laboratory-based study on patients with Parkinson’s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatology. 2014; 14:1.
21. Vidovic A, Arsic-Arsenijevic V, Tomin D, Djunic I, Jakovic R, Loncar Z, **Barac A**. Proven invasive pulmonary mucormycosis successfully treated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case report. J Med Case Rep. 2013; 7:263.

**RAD U ČASOPISU KOJI JE UKLJUČEN U BAZU PODATAKA MEDLINE**

1. **Barać A**. Novi dijagnostički kriterijumi za gljivični rinosinuzitis i nove metode za otkrivanje gljiva u sinusima. Srpski Arhiv za celokupno lekarstvo, 2023; 11(1): 29-58.

2. Vujović A, Stevanović G, Milošević B, **Barać A**, Despotović A, Jug M, Milošević I. Uticaj COVID-19 pandemije na razvoj amtimikrobne rezistencije. Svet rada (naučni časopis za pitanja bezbednosti i zdravlja na radu, medicine rada i zaštite životne sredine za jugoistočnu Evropu), 2022; 19(3): 273-336.

3. Lavadinović L, **Barać A**. Importovane bolesti kao stalna pretnja. Acta Clinica, 2018.

**RAD U ČASOPISU MEDICINSKA ISTRAŽIVANjA**

1. **Barać A**, Despotovic A, Vujovic A, Cucanic T, Cucanic K, Mitic A, Stjepanovic M Maric N, Filipovic A, Vlaskovic J, Knezevic N, Stojanovic M, Micic J, Stevanovic G. Differences in clinical and laboratory characteristics in patients infected with COVID-19 during different epidemic waves. Medicinska istraživanja 2023; 56(4):1-9.

**IZVOD U ZBORNIKU MEĐUNARODNOG SKUPA**

1. Bonten MMJ**, Barac A**. The Ecraid perpetual observational study on ventilator-associated pneumonia: a solid operational backbone ready for embedding clinical studies (No. 01564). ECCMID 2024, Barcelona, Spain.
2. Salmanton-Garcia J, **Barac A**. Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort Study. ECCMID 2024, Barcelona, Spain.
3. Salmanton-Garcia J, **Barac A**. Assessing Diagnostic Capabilities and Treatment Accessibility for Invasive Fungal Infections in the Balkan Region. ECCMID 2024, Barcelona, Spain.
4. Hernandez Padilla AC, Jackson, H, Dee Kraker ME, **Barac A**, Garot D, Bonten MMJ. Characterising complicated urinary tract infections (cUTI): preliminary results of the Ecraid perpetual observational study on cUTI (POS-cUTI). ECCMID 2024, Barcelona, Spain
5. Van Braeckel E, Van Acker L, Salzer HJ, Seidel S, Cornely O, Hoenigl M, Alastruey-Izquierdo A, Hennequin C, Godet, **Barac A**, Flick H. CPAnet Registry – An International Chronic Pulmonary Aspergillosis Registry (No. 26759). Eureopen Respiratory Society Congress (ERS), ERS virtual Congress, 2020.
6. Hernandez Padilla AC, Jackson, H, Dee Kraker ME, **Barac A**, Garot D, Bonten MMJ. Need for new criteria for Ventilator Associated Pneumonia to standardize evaluation of clinical cure (No. 001161). ESICM, 2024, Barcelona, Spain.
7. Matthias Egger, Jon Salmanton-García, Philipp Koehler, Jean-Pierre Gangneux, Maiken C. Arendrup, **Aleksandra Barac**, Sevtap Arikan-Akdagli, Matteo Bassetti, Oliver Cornely, Martin Hoenig. Baseline risk factors for mortality in Candidemia – The role of C. auris and emerging Candida species. ECCMID 2023, Copenhagen, Denmark.
8. Salmanton-Garcia J, **Barac A**. Improved clinical outcome of COVID-19 in haematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine. ECCMID 2023, Copenhagen, Denmark.
9. Salmanton-Garcia J, **Barac A**. Molnupiravir compared to nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies. ECCMID 2023, Copenhagen, Denmark.
10. Yahav D, **Barac A**, Righi E, Nasim A. Ethics and Infectious Diseases: A Global Survey. ECCMID 2022, Lisbon, Portugal.
11. Sadegh Khodavaisy, **Aleksandra Barac**. Mucormycoses in patients with COVID-19: multicenter study. ECCMID virutal 2021.
12. **Barac A.** The importance of laboratory biomarkers in the diagnosis of fungal infections. 13th SEEC (Southeast European Conference on Chemotherapy and infection). Belgrade, Serbia, 2023
13. **Barac A.** Update on diagnosis and treatment of dermatophytes. 11th Trends in Medical Mycology (TIMM), Athens, Greece, 2024.
14. **Barac A.** Update on diagnosis and treatment of invasive fungal infections. 8th Congress of Asia-Pacific Society for Medical Mycology, Kyoto, Japan, 2024.
15. **Barac A.** New antifungal drugs. 22nd Congress of International Society for Human and animal mycology (ISHAM). Brazil, 2024.
16. **Barac A.** Chronic Pulmonary Aspergillosis - where do we stand? 21st Congress of International Society for Human and animal mycology (ISHAM). New Delhi, India, 2022.
17. **Barać A**. United airway Aspergillus infections: true or false? 8th AAA 2018, Lisbon, Portugal
18. Marina Pekmezović, Valentina Arsić Arsenijević, **Barac A**, Ferry Hagen, Jacques Meis. Genotypes, susceptibility profile and virulence of Cryptococcus neoformans clinical isolates from Serbia. 9th International Conference on Cryptococcus and cryptococcosis, 15-19 May 2014, Amsterdam, The Netherlands. Mycosеs 57 (Suppl.1):97.
19. Marina Pekmezović, **Barac A,** Ferry Hagen, Valentina Arsić Arsenijević. Cryptococcus neoformans - genotypes and antifungal susceptibility profile of clinical strains in Serbia. 47th Days of preventive medicine, 24-27 September 2013, Niš, Serbia. Abstract book: p54.
20. **Barac A,** Marina Pekmezović, Ana Vidović, Dejan Stojaković, Bojana Bjelogrlić, Valentina Arsić Arsenijević. Invasive mucormycosis at patients with neoplasms in Serbia – report of two cases. 47th Days of preventive medicine, 24-27 September 2013, Niš, Serbia. Abstract book: p53.
21. **Barac A,** Dragana Ivanovic, Marina Pekmezovic, Igor Lukovic, Valentina Arsic Arsenijevic. Secondary soluble metabolites of Aspergillus fumigatus and its influence on inhibition of human WISH, CaCo and DU-145 cancer cell proliferation. 5th Advances Against Aspergillosis, 26-28 January 2012, Istanbul, Turkey. Abstract book: p198.
22. Arsić Arsenijević V, **Barać A**, Vidović A, Suvajdžić N. Anti-Aspergillus Antibodies in Hematological Patients Suspected for Developing Invasive Aspergillosis. 5th Advances against Aspergillosis, 26-28 January 2012, Istanbul, Turkey. Abstract book: p144.
23. Pekmezovic M, Lukovic I, **Barac A,** Arsic Arsenijevic V. Antifungal activity of Eucalyptus globulus oil against Candida species. 2nd Workshop: Medical Mycology: From Basic Science to Clinical Needs, 8-10 December 2011, Vienna, Austria. Abstract book: p58.
24. Lukovic I, Pekmezovic M, **Barac A,** Arsic Arsenijevic V. Antifungal activity of 11 essential oils against Microsporum nanum. 2nd Workshop "Medical Mycology: From Basic Science to Clinical Needs", 8-10 December 2011, Vienna, Austria. Abstract book: p58.
25. Pekmezović M, Rajković K, **Barac A**, Arsić Arsenijević V. Synergistic antifungal effect of essential oils on Aspergillus flavus: kinetic model development and its optimization. Belgrade International Molecular Life Science Conference for Students, 15-18 January 2015, Belgrade, Serbia. Abstract book: 53.
26. **Barac A**, Pekmezović M, Vidovic A, Stojakov D, Bjelogrlic B, Boljevic D, Arsić Arsenijević V. Invasive mucormycosis in patients with neoplasms in Serbia –report of two cases. Winter Biology Students in Europe Conference 2-8 February 2014, Arandjelovac, Serbia. Abstract book:18-19.
27. Pekmezović M, **Barać A**, Arsić Arsenijević V. Genotypes, susceptibility profile and virulence of Cryptococcus neoformans clinical isolates from Serbia. Winter Biology Students in Europe Conference 2-8 February 2014, Arandjelovac, Serbia. Abstract book:63-64.
28. Janovic A, Antic S, **Barac A**, Arsic Arsenijevic V, Rakocevic Z. Radiological characteristics of allergic fungal sinusitis i patients with clinically diagnosed chronic rhinosinusitis: preliminary results. 18th Congress of the Balkan Stomatological Society (BaSS), 25-28 April 2013, Skopje, Macedonia.
29. Pekmezović M, **Barać A**, Hagen F, Arsić Arsenijević V. Cryptococcus neoformans - genotypes and antifungal susceptibility profile of clinical strains collected in Serbia over a 20-year period. 47th Days of preventive medicine, 24-27 September 2013, Nis, Serbia.
30. **Barac A**, Pekmezovic M, Vidovic A, Stojakov D, Bjelogrlic B, Arsic Arsenijevic V. Invasive mucormycosis in patients with neoplasm in Serbia – report of two cases. 47th Days of preventive medicine, 24-27 September 2013, Nis, Serbia.
31. Arsić Arsenijević V, **Barać A**, Ratkov E, Vidović A, Suvajdžić N, Janić D. Screening for Mannan and Anti-Candida Antibodies in Haematological Patients Suspected for developing Invasive Candidosis. 5th Trends in Medical Mycology (TIMM-5), 9-12 October 2011, Valencia, Spain.
32. **Barać A**, Ratkov E, Srebro D, Arsić Arsenijević V. Disseminated fusariosis at high risk children and adults during two years’ period in Serbia. 5th Trends in Medical Mycology (TIMM-5), 9-12 October 2011, Valencia, Spain.
33. **Barać A**, Srebro D, Arsić Arsenijević V, Diagnosis of invasive fungal infection by detection of early laboratory biomarkers in a child with anemia aplastica. 5th Trends in Medical Mycology (TIMM-5), 9-12 October 2011, Valencia, Spain.
34. **Barać A**, Bjelogrlić B, Suvajdžić N, Arsić Arsenijević V. Nosocomial outbreak of Candida tropicalis septicemia in patientс with acute myeloid leukemia. 5th Trends in Medical Mycology (TIMM-5), 9-12 October 2011, Valencia, Spain.
35. **Barać A**, Srebro D. Laboratory diagnosis of bronchopulmonary aspergillosis. 51. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem 23-27 April 2010, Ohrid, Macedonia.
36. Srebro D, **Barać A**. Enzymes methods in diagnosis of allergic bronchopulmonary aspergilloses and invasive aspergillosis in children with cystic fibroses and hematological malignancies. 51. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem 23-27 April 2010, Ohrid, Macedonia.
37. **Barać A**, Bjelogrlić B, Biševac J. Prisustvo meticilin rezistentnog Staphylococcus Aureus-a u nosu kod studenata Medicinskog fakulteta u Beogradu. 49. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem, 28 April - 2 May 2008, Lepenski Vir, Serbia.
38. Biševac J, **Barać A**, Bjelogrlić B. Podtipovi ishemijskog moždanog udara: Analiza povezanosti poremećaja insulinske senzitivnosti i markera inflamatornog odgovora u pacijenata sa tipom 2 dijabetesa i nedijabetičara. 49. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem, 28 April - 2 May 2008, Lepenski Vir, Serbia.
39. Bjelogrlić B, **Barać A**, Biševac J. Analiza povezanosti aktivnosti antioksidativnih enzima i insulinske rezistencije u različitim podtipovima ishemijskog moždanog udara u pacijenata sa tipom 2 dijabetesa i nedijabetičara. 49. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem, 28 April - 2 May 2008, Lepenski Vir, Serbia.
40. **Barac A**, Pekmezovic M, Kostic M, Arsic Arsenijevic V. Chronic rhinosinusitis - association of recalcitrant nasal polyposis and fungal finding in polyp’s single-cell suspension. International student congress 2015, 4-6 June 2015, Graz, Austria.
41. **Barac A**, Pekmezovic M, Kostic M, Arsic Arsenijevic V. Rhino-cerebral mucormycosis at high risk patients - case reports. International student congress 2015, 4-6 June 2015, Graz, Austria.
42. **Barac A**, Pekmezovic M, Kostic M, Arsic Arsenijevic V. Association of recalcitrant chronic rhinosinusitis with nasal polyposis and fungal finding in polyps single-cell suspension. 7th Trends in Medical Mycology, 9-12 October 2015, Lisbon, Portugal.
43. Pekmezovic M, Rajkovic K, **Barac A**, Kostic M, Arsic Arsenijevic V. Kinetic modeling of Aspergillus fumigatus biofilm developed in vitro using digital image analysis. 7th Trends in Medical Mycology, 9-12 October 2015, Lisbon, Portugal.
44. Pekmezovic M, **Barac A**, Kostic M, Arsic Arsenijevic V. Invasive candidiasis in intensive care units in Serbia: preliminary results on species distribution, antifungal susceptibility profile and biofilm formation of Candida spp. isolates from blood. 7th Trends in Medical Mycology, 9-12 October 2015, Lisbon, Portugal.
45. **Barac A**, Pekmezovic M, Vidovic A, Stojakov D, Bjelogrlic B, Boljevic D, Arsić Arsenijević V. Invasive mucormycosis in patients with neoplasms in Serbia –report of two cases. Winter Biology Students in Europe Conference 2-8 February 2014, Arandjelovac, Serbia. Abstract book: 18-19.
46. Pekmezović M, **Barać A**, Arsić Arsenijević V. Genotypes, susceptibility profile and virulence of Cryptococcus neoformans clinical isolates from Serbia. Winter Biology Students in Europe Conference 2-8 February 2014, Arandjelovac, Serbia. Abstract book: 63-64.
47. **Barac A**, Pekmezovic M, Rajkovic K, Rakocevic Z, Janovic A, Bracanovic Dj, Stosovic R, Tomic Spiric V. Mathematical modelling and image analysis: possible clinical application in practice as a predictor of fungal rhinosinusitis. 60th Anniversary Congress of European Academy of Allergology and Clinical Immunology 11-15 June 2016, Vienna, Austria.
48. **Barac A**, Pekmezovic M, Kostic M, Aleksic E, Tomic Spiric V. Unusual early signs of invasive candidiasis. International student congress 2016, 26-28 May 2016, Graz, Austria.
49. **Barac A**, Pekmezovic M, Arsic Arsenijevic V. The fungi: silent neighbors or hidden threat? ECMM Educational symposium, Tel Aviv, Israel, 14-17 February 2016
50. **Barac A**. Role of fungi and diagnostic of invasive fungal infections in febrile neutropenia. 7th Eurasia congress of infectious diseases (EACID), 1-3 October 2015 Tbilisi, Georgia.
51. Igor S. Lukovic, Marina G. Pekmezovic, **Barac A,** Valentina S. Arsic Arsenijevic. Antifungal activity of 11 essential oils against Microsporum nanum. 2nd Workshop "Medical Mycology: From Basic Science to Clinical Needs", 8-10 December 2011, Vienna, Austria. Abstract book: p58.

**IZVOD U ZBORNIKU NACIONALNOG SKUPA**

1. Micić J, **Barać A**. COVID-19 vakcinacija pre i tokom trudnoće. KME „Humana reprodukcija u vrtlogu pandemije COVID-19“, SANU 13.12.2021.
2. **Barac A**. Multidisciplinarni priscup prevenciji, dijagnostici i lečenju invazivnih gljivičnih infekvcija. UMS Series, Belgrade, Serbia, 2023.
3. **Barac A**. Gljivične infekcije kod HIV pozitivnih i HIV negativnih pacijenata – ima li razlike? Infekcije kod imunosuprimiranih osoba – Problemi prepoznavanja, dijagnostike i lečenja. Nacionalni kongres sa međunarodnim učešćem. Regionalna Lekarska komora Srbije. Beograd, Srbija, 2024.
4. **Barac A**. RSV kod imunokompromitovanih: common cold ili infekcija koja zahteva vakcinaciju? KME »Virusne infekcije kod imunokompromitovanih bolesnika«. Beograd, Srbija, 2024.
5. **Barac A.** Gljivična oboljenja gornjih respiratornih puteva – savremeni pristup. Kongres Regionalne Lekarske komore, Beograd, Srbija 2023.
6. Pekmezović M, **Barac A,** Arsić Arsenijević V. Ispitivanje osetljivosti Stachybotrys chartarum izolovane iz sputuma pacijentkinje obolele od plućne aspergiloze na 12 različitih etarskih ulja. 3. Simpozijum Dijagnoza i terapija gljivičnih oboljenja, 1-2. mart 2012, Beograd. Zbornik radova: 74-5.
7. **Barac A**, Marina Pekmezović, Aleksandra Dudvarski Ilić, Predrag Minić, Aleksandar Džamić, Sanja Mitrović, Valentina Arsić Arsenijević. Alergijski fungalni sinuzitis - asocijacija sa alergijskom bronhopulmonalnom mikozom i kriterijumi za dijagnostiku. 3. Simpozijum Dijagnoza i terapija gljivičnih oboljenja, 1-2. mart 2012, Beograd, Srbija. Zbornik radova: 74-75.
8. Adžić J, Luković I, Pekmezović M, **Barac A**, Arsić Arsenijević V. Vrste rodova Candida i Aspergillus kao izazivači otomikoza kod pacijenata sa i bez prethodne otološke hirurške intervencije. 3. Simpozijum Dijagnoza i terapija gljivičnih oboljenja, 1-2.03.2012, Beograd. Zbornik radova: 55.
9. **Barac A**, Marina Pekmezović, Aleksandar Džamić, Sanja Mitrović, Valentina Arsić Arsenijević. Epidemija Fusarium-a kod dece obolele od osteosarkoma nakon hirurške intervencije i ugradnje endoproteza – prikaz slučaja. 3. Simpozijum Dijagnoza i terapija gljivičnih oboljenja, 1-2. mart 2012, Beograd, Srbija. Zbornik radova: 74-75.
10. Čolovic N, Suvajdzic N, Arsic Arsenijevic V, **Barac A**, Tomin D. Fungemia with candida tropicalis in patients with acute myeloid leukemia. 3rd Symposium on Diagnosis and Therapy of Fungal Diseases, 1-2 March 2012, Belgrade, Serbia
11. Adžić J, Luković I, **Barać A**, Pekmezović M, Arsić Arsenijević V. Vrste rodova Candida i Aspergillus kao izazivači otomikoza kod pacijenata sa i bez prethodne otološke hirurške intervencije. 3rd Symposium on Diagnosis and Therapy of Fungal Diseases, 1-2 March 2012, Belgrade, Serbia
12. Pekmezovic M, **Barac A**, Arsic Arsenijevic V. Susceptibility testing in 12 different essential oils of Stachybotrys chartarum isolated from sputum of patient suffering from pulmonary aspergillosis. 3rd Symposium on Diagnosis and Therapy of Fungal Diseases, 1-2.03.2012, Belgrade.
13. Vidović A, Tomin D, Suvajdžić Vuković N, Čolović N, Đunić I, **Barać A**, Đurašinović V, Virijević M, Lazić Lj, Mihaljević B, Arsić Arsenijević V. Invazivna zigomikoza pluća kod bolesnika sa akutnom mijeloblastnom leukemijom – prikaz bolesnika. 3rd Symposium on Diagnosis and Therapy of Fungal Diseases, 1-2 March 2012, Belgrade, Serbia
14. Milosevic G, Kovacevic J, Rodic P, Dokmanovic L, **Barac A**, Arsic Arsenijevic V, Janic D. Characteristics of invasive pulmonary aspergillosis in children with malignancies. 4th Symposium on Diagnosis and therapy on fungal diseases 26-28.02.2016, Belgrade, Serbia. Abstract book: 4-5.
15. Kovacevic J, Milosevic G, Lazic J, Rodic P, Dokmanovic L, **Barac A**, Arsic Arsenijevic V, Janic D. Fungal infections of paranasal sinuses caused by Cladosporium in patient with acute myeloid leukaemia. 4th Symposium on Diagnosis and therapy on fungal diseases 26-28.02.2016, Belgrade. Abstract book: 5-6.
16. Rajkovic K, Pekmezovic M, **Barac A**, Arsic Arsenijevic V. Innovations in medical mycology - use of mathematic and visualisation models. 4th Symposium on Diagnosis and therapy on fungal diseases 26-28 February 2016, Belgrade, Serbia. Abstract book: 8-9
17. Arsic Arsenijevic V, **Barac A**, Pekmezovic M, Rakocevic Z, Tomic Spiric V. Evaluation of sampling assays for induction of sinonasal secretion and for the fungi recovery from the sinuses. 4th Symposium on Diagnosis and therapy on fungal diseases, 26-28.02.2016, Beograd. Abstract book: 45.
18. Čolović N, Arsić Arsenijević V, **Barać A,** Suvajdžić N, Tomin D. Mucormycosis of the paranasal sinuses in a patient with acute myeloid leukemia. 4th Symposium on Diagnosis and therapy on fungal diseases, 26-28.02.2016, Beograd. Abstract book: 2.

**b) Rukovo**đ**enje i učešće na projektima**

2024 – u toku rukovodilac projekta POS-ARI-ER ECRAID mreže

2023 – u toku rukovodilac projekta POS-VAP ECRAID mreže

2022 – u toku rukovodilac projekta POS-cUTI ECRAID mreže

2020 – 2021, Saradnik na projektu „FORACOVID“ – Fond za nauku Republike Srbije (Science Fund of the Republic of Serbia Special Research Program on COVID-19), Institut za Sudsku medicinu, Medicinski Fakultet Univerziteta u Beogradu

2020 –2024, Rukovodilac projekta “CPAnet – Chronic Pulmonary Aspergillosis research network” pri Evropskom respiratornom udruženju (European Respiratory Society/ERS)

2017 – 2019, Rukovodilac za Srbiju projekta PREPARE MERMAID-ARBO (Oxford University)

2016 – 2019, Saradnik na projektu „*Functional, functionalized and advanced materials*”, III45005, Ministarstvo za nauku i tehnološki razvoj Srbije

2011 – 2015, Saradnik na projektu „*The importance of early detection of laboratory biomarkers to reduce the mortality of invasive fungal infections in Serbia*”, OI175034, Ministarstvo za Nauku i tehnološki razvoj Srbije

Dr Barać je bila angažovana na nekoliko međunarodnih studija kao istraživač i koordinator koje su se bavile različitim temama iz oblasti infektivnih bolesti (arbovirusi, kandidijaza, aspergiloza, sezonski grip, tuberkuloza, kriptokokoza, COVID-19), a koje su rezultirale zajedničkim publikacijama u časopisima sa JCR liste, kao i formiranju vodiča za lečenje nekih od navedenih infektivnih bolesti.

**c) Citiranost**

Prema podacima sa Kobsona, Scopus-a i iz Univerzitetske biblioteke radovi sa JCR liste u kojima je kandidat bio autor ili koautor citirani su u **85.306** navrata, a Hirshov index (**H-index**) iznosi **63**.

**d) Organizovanje naučnih sastanaka i simpozijuma**

2025. Član organizacionog odbora kongresa Međunarodnog udruženja za mikologiju (ISHAM) u Brazilu 2025. god.

2024. Član organizacionog odbora ESCMID Technical Workshop, u Beogradu, 24-27 oktobar 2024. Beograd, Srbija

2022. Organizator trodnevnog kursa ESCMID TAE Leadership Academy 28-30. oktobar 2022. Beograd, Srbija

2022. Organizator trodnevnog Antimicrobial stewardship certificate module: "Antimicrobial stewardship: a compentency-based approach" 25-27. novembar 2022 (kurs je sastavni deo dvogodišnje sertifikovane Evropske subspecijalizacije iz Antimicrobial stewardship) Beograd, Srbija

2022. Organizator 4-nedeljnog kursa ESCMID Ethics Advisory Committee Course: Ethical issues in Infectious Diseases, online, maj 2022.

2022. Član Organizacionog odbora »ESCMID Early career mycoplasma and chlamydia researcher conference«, online, septembar 2022.

2022. Organizator ECCMID 2022 Open foruma: Ethics in Infectious Diseseas (23. april 2022)

2021. Član Organizacionog odbora 4. Kongresa alergologa i kliničkih imunologa Srbije (UAKIS) a međunarodnim učešćem “Interdisciplinarne teme u alergologiji i kliničkoj imunologiji “

2019. Član Organizacionog odbora Alergološkog simpozijuma „Prof. dr Vladimir Spužić“, Beograd, Srbija

2019. Član Organizacionog odbora 5th Congress of European ORL-HNS, Brisel, Belgija

2018 – 2020. Organizator ECCMID TAE day (Beč, Amsterdam, Pariz)

2018. Član Organizacionog odbora Evropskog kongresa Eureopean Rhinology Society (ERS), London, UK

2018. Član Organizacionog obdora 2nd. Balkan Rhino Forum (BRF), Beograd, Srbija

2017. Član Organizacionog obdora 4th European Congress ORL-NHS, Barselona, Španija

2017. Član Organizacionog odbora 1. Kongresa Rinologa Srbije i 2. Rinološkog simpozijuma (RAAS), Beograd, Srbija

03.2015. Član Organizacionog odbora skupa „Dijagnoza gljivičnih infekcija – od uzorka do rezultata“, Društvo Medicinskih Mikologa Srbije (DMMS), Beograd, Srbija

01-04.2012. Član i Generalni sekretar Organizacionog odbora Naučnog simpozijuma „3. Simpozijum o dijagnozi i terapiji gljivičnih oboljenja“, Društvo Medicinskih Mikologa Srbije (DMMS), Beograd, Srbija.

**e) Druga dostignuća (recenzije, recenzije u časopisima)**

Recenzent za časopise: The Lancet, Nature, PLoS One; Scientific reports; Mycoses; European Journal of Clinical Microbiology and Infectious Diseases; Frontiers in Microbiology; Frontiers in Public Health; Frontiers in Medicine; Journal of Medical Microbiology; Medical Mycology; MicrobiologyOpen; Science of the Total Environment; Clinical Otolaryngology; Clinical and Translational Allergy; Rhinology; Respiration; Journal of the European Academy of Dermatology and Venereology; Respiration; Current Biomarker Findings; International Journal of COPD, Journal of Pain Research; Therapeutics and Clinical Risk Management; Journal of Patience Preference and Adherence; Clinical Interventions in Aging; International Journal of General Medicine...

**Đ. OCENA O REZULTATIMA NAUČNOG I ISTRAŽIVAČKOG RADA**

Naučno-istraživački rad dr sci med. Aleksandre Barać ima jasan kontinuitet, počevši od pohađanja seminara Istraživačke stanice Petnica u gimnazijskom periodu, preko izrade i odbrane doktorske disertacije, do samostalnog rukovođenja međunarodnim projektima u sadašnjem periodu. Dr Aleksandra Barać je uz ostalu dokumentaciju priložila spisak i fotokopije svih navedenih radova. Navedene su ukupno 292 publikacije i to 224 radova objavljenih *in extenso*, 68 izvoda, a od toga je 208 radova sa JCR liste (u 19 radova je prvi autor, u 21 rad je nosilac rada, a u ostalih 182 radova je saradnik). Aktivni je član ekspertskih grupa za pisanje vodiča za lečenje nekoliko različitih infektivnih bolesti (COVID-19, kandidijaze, hronične plućne aspergiloze...), i bila je koautor vodiča za lečenje COVID-19 Evropskog udruženja infektologa (ESCMID). Takođe član je ekspertske grupe Ministarstva za nauku Republike Srbije za formiranje strategije za nauku za naredni 5-godišnji period kao i za pisanje UNESCO smernica za Otvorenu nauku, i bila je koautor smernica za otvorenu nauku. Na osnovu priloženih publikacija može se zaključiti da su interesovanja kandidata vezana za različite oblasti infektologije, a prevashodno za gljivične infekcije, antimikrobnu terapiju, antimikrobnu rezistenciju i nejasna febrilna stanja. Dr Barać je član Akademije Medicinskih Nauka SLD, počasni član Evropskog udruženja infektologa (*fellow of* ESCMID) i počasni član Evropskog udruženja za medicinsku mikologiju (*fellow of* ECMM), kao i član brojnih upravnih odbora međunarodnih udruženja koji se bave infektivnim bolestima i bolestima respiratornog sistema. Dr Barać je dugogodišnji član uredništva više inostranih časopisa sa JCR liste, kao i recenzent za nacionalne projekte Ministarstva više različitih država (Italija, Španija, Belgija, Srbija).

Dr Aleksandra Barać je u vidu studijskih boravaka provela po više meseci, u periodu 2010–2020. godine, u evropskim univerzitetskim i naučnim centrima u Beču (Austrija), Sardiniji (Italija), Londonu (Engleska), Salzburgu (Austrija), Najmengenu (Holandija) i Buenos Airesu (Argentina) i na taj način iskazala tendenciju ka kontinuiranom usavršavanju u naučno-istraživačkom radu.

Istraživačka delatnost kandidatkinje ukazuje da je sposobna da samostalno i kritički pristupi istraživanju i rešavanju naučnih problema, kao i da je u potpunosti ovladala metodologijom koja se primenjuje u savremenim istraživanjima. Višegodišnji kontinuiran naučno-istraživački rad dr Barać doprinosi proširivanju bazičnih saznanja iz oblasti etiologije i patogeneze gljivičnih oboljenja i njihovom lečenju.

Dr Barać je bila angažovana na nekoliko kliničkih studija i međunarodnih studijskih saradnji kao istraživač i koordinator koje su se bavile različitim temama iz oblasti infektivnih bolesti (arbovirusi, kandidijaza, aspergiloza, sezonski grip, tuberkuloza, kriptokokoza, COVID-19), a koje su rezultirale zajedničkim publikacijama u časopisima sa JCR liste, kao i formiranju vodiča za lečenje nekih od navedenih infektivnih bolesti.

Na osnovu analize podnetog materijala, broja i kvaliteta objavljenih radova u međunarodnim časopisima i saopštenih na međunarodnim i domaćim naučnim skupovima, učešća na međunarodnim i domaćim projektima (uključujući i projekte Ministarstva prosvete, nauke i tehnološkog razvoja), studijskih boravaka u inostranim univerzitetskim naučnim centrima, nagrada i drugih naučnih i stručnih aktivnosti kandidata, i uvida u priloženu dokumentaciju kandidatkinje Aleksandre Barać, doktora medicine, doktora medicinskih nauka i infektologa, zaključuje se da kandidatkinja ispunjava sve uslove za sticanje nastavnog zvanja.

**E. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE**

Dr Aleksandra Barać svakodnevno učestvuje u izvođenju različitih oblika nastave na Medicinskom fakultetu u Beogradu kroz svoj posvećen i savestan rad sa studentima, ne samo u okviru redovnog programa, već i angažovanjem van obaveznog programa vežbi kroz edukaciju posebno zainteresovanih studenata i aktivnom saradnjom sa studentskom organizacijom.

**Stručno-profesionalni doprinos**

Kandidat dr Aleksandra Barać pored naučno-istraživačkog angažovanja u oblasti Infektivnih bolesti aktivno učestvuje u kliničkom radu kao specijalista infektologije i subspecijalista kliničke farmakologjie i farmakoterapije u Klinici za infektivne i tropske bolesti UKCS. Tokom kliničkog staža učestvovala je u radu Klinike tokom epidemije West Nile virusne infekcije, epidemije malih boginja, epidemije Influenze, i COVID-19 pandemije. Radi u odeljenju za Kliničku farmakoterapiju Klinike za infektivne i tropske bolesti, UKCS i deo je tima za lečenje nejasnih febrilnih stanja. Svakodnevno učestvuje u radu ambulante odeljenja kroz koju godišnje bude pregledano više hiljada pacijenata sa nejasnim febrilnim stanjem, multirezistentnim infekcijama i gljivičnim infekcijama. Pored pomenutog, dr Aleksandra Barać je aktivni član Konzilijuma za racionalnu primenu antimikrobne terapije Univerzitetskog Kliničkog centra Srbije koji sačinjava multidisciplinarni tim i koji se okuplja jednom nedeljno i donosi odluku o daljem lečenju infekcija kod teško obolelih pacijenata. Takođe, dr Barać aktivno učestvuje i u lečenju bolesnika sa ostalim infektivnim i tropskim bolestima.

**Doprinos akademskoj i široj zajednici**

**Značajno strukovno, nacionalno ili međunarodno priznanje za naučnu ili stručnu delatnost**

2024. Priznanje časopisa The Lancet (M21a; IF 71.42) za globalni doprinos u oblasti gljivičnih infekcija „Researcher of the month: Aleksandra Barac - a global focus on fungal infections. Lancet Infect Dis. 2024 Mar; 24(3):236. (https://doi.org/10.1016/S1473-3099(24)00087-2).

2024. Nagrada Journal of Fungi (M21) za Najboljeg mladog istraživača

2023. Nagrada za Mlade istraživače Medicinskog Fakulteta Univerziteta u Beogradu

2023. Izabrana u zvanje „Naučni savetnik“, uža oblast Infektivne bolesti, Ministarstvo za Nauku, Republike Srbije

2023. Dobitnik stipendije Američko-austrijske fondacije (AAF) za pohađanje edukativne škole iz oblasti Infektivnih bolesti, Open Medical Institute, Columbia University (New York, USA). Salzburg, Austria

2022. Počasni član (Fellow of ESCMID / FESCMID) Evropskog udruženja infektologa i kliničkih mikrobiologa (European Society for Clinical Microbiology and Infectious Diseases/ESCMID)

2019. Nagrada za najbolju ženu u nauci (2019 UNESCO-L’Oréal Award for Women in Science) dodeljeno od strane UNESCO, L'Oreal-a i Ministarstva za nauku i tehnološki razvoj Srbije

2018. Počasni član (Fellow of ECMM/FECMM) Evropskog udruženja za kliničku mikologiju (European Confederation for Medical Mycology/ECMM)

2018. Nagrada Evropskog udruženja infektologa i kliničkih mikrobiologa (European Society for Clinical Microbiology and Infectious Diseases/ESCMID) za izvanredna dostignuća u oblasti infektologije (TAE Outstanding Award for the Training achievements)

2017. Nagrada Evropskog udruženja za kliničku mikologiju (European Confederation for Medical Mycology/ECMM) za izvanredna dostignuća u oblasti dijagnostike i lečenja gljivičnih infekcija

2016. Nagrada i stipendija Evropske akademije za alergologiju i kliničku imunologiju za postdoktorsko istraživanje i boravak u Univerzitetu u Kaliforniji, Sjedinjene Američke države, mentor Prof. Daniels-Wels Tracy (The University of California, Los Angeles UCLA, LA, USA)

2016. Nagrada Evropskog udruženja rinologa (ERS) za najbolji rad odabran od strane ERS Board na kongresu European Academy of Allergology and Clinical Immunology (EAACI) u Beču, Austrija

2016. Nagrada Evropske akademije za alergologiju i kliničku imunologiju (EAACI) za najbolji abstrakt i učešće na 60. kongresu EAACI u Beču, Austrija

2016. Nagrada Evropskog udruženja za kliničku mikrobiologiju i infektivne bolesti (ESCMID) za učešće na 25. ECCMID-u u Amsterdamu, Holandija

2016. Nagrada Evropskog udruženja za medicinsku mikologiju (ECMM) za postignute rezultate za mlade naučnike i za učešće na ESMM edukativnom skupu u Tel Avivu, Izrael

2015. Nagrada Evropske federacije mikrobiologa (FEMS) za učešće na međunarodnom kongresu "7th Trends in Medical Mycology" u Lisabonu, Portugal.

2015. Dobitnik stipendije Američko-austrijske fondacije (AAF) za pohađanje edukativne škole iz oblasti Infektivnih bolesti, Open Medical Institute, Columbia University (New York, USA). Maj 2015, Salzburg, Austria - tokom trajanja seminara osvojila nagradu za najbolji prikaz kliničkog slučaja.

2015. Nagrada i stipendija Evropskog udruženja Rinologa (ERS) za studijski boravak u Univerzitetskom koledžu u Londonu (ERS fellowship for the Endoscopic approach to rhinosinusitis in sinonasal disease in University college of London, UK)

2015. Stipendija Austrijskog Ministarstva za nauku i internacionalu saradnju (OeAD) za studijski boravak u cilju izrade doktorske disertacije i usavršavanje na Medicinskom Univerzitetu u Beču, Max F. Perutz Laboratory, Vienna Biocenter, istraživačka grupa Prof. Karl Kuhlera, Beč, Austrija

2015. Nagrada „ISC Travel award” za učešće na Internacionalnom studentskom kongresu (ISC) u Gracu, Austrija

2011. Stipendiju Radboud Univerzitetske bolnice za učešće na usavršavanju pod nazivom "Laboratorijska dijagnoza invazivnih gljivičnih infekcija" na Radboud Univerzitetskoj bolnici u Nijmegenu, Holandija

2011. Nagrada Evropskog udruženja za kliničku mikologiju (European Confederation for Medical Mycology/ECMM) za mlade naučnike (ECMM Young Investigator Award)

2008. Stipendija za talentovane studente Ministarstva Omladine i sporta od 2008. god.

**Članstvo u stručnim ili naučnim asocijacijama u koje se član bira ili koje imaju ograničen broj članova**

Dr Barać je član Akademije Medicinskih nauka Srpskog Lekarskog Društva od 2022. godine.

Od 2024. član „World minds“

Od 2012. član “ European Respiratory Society” (ERS)

Od 2012. član i stipendista „European Academy of Allergy and Clinical Immunology“ (EAACI)

Od 2011. član i stipendista “ European Rhinology Society” (ERS)

Od 2010. član “International Society for Human and Animal Mycology” (ISHAM)

Od 2010. član i stipendista “European Confederation of Medical Mycology” (ECMM)

Od 2010. član i stipendista "Federation of European Microbiological Societies" (FEMS)

Od 2009. član i stipendista “European Society of Clinical Microbiology and Infection Diseases” (ESCMID)

Od 2001. član udruženja “MENSA”.

**Uređivanje časopisa ili monografija priznatih od strane resornog ministarstva za nauku;**

**Urednik/član uredništva časopisa:**

Od 2025 – Journal of Advanced Research (M21a kategorija, IF 11.7)

Od 2022 – „Mycoses” (M21a kategorija, IF 4.931)

Od 2018 – „Frontiers in Microbiology” (M21a kategorija, IF 6.064)

Od 2018 – „Frontiers in Medicine“ (M21a kategorija, IF 5.093)

Od 2018 – „Frontiers in Public Health“ (M21a kategorija, IF 6.461)

Od 2018 – „BMC Public Health“ (M21 kategorija, IF 4.135)

Od 2018 – „Transactions of the Royal Society of Tropical Medicine and Hygiene“ (M22 kategorija, IF 2.455)

Od 2017 – „PLoS One” (M22 kategorija, IF 3.752)

Od 2015 – „The Journal of Infection in Developing countries” (M23 kategorija, IF 2.552)

**Predsedavanje nacionalnim ili međunarodnim strukovnim ili naučnim organizacijama**

1. 2024-2028, Podpredsednik komiteta za Preteće infekcije (Emerging Infections Committee) pod okriljem Evropskog udruženja za Infektivne bolesti i kliničku mikrobiologiju (European Society for clinical microbiology and infectious diseases/ESCMID)

2. 2022-2025, Predsednik za mlade Međunarodnog udruženja za gljivične infekcije (International Society for Human and animal mycology/ISHAM)

3. 2018-2021, Predsednik za mlade Evropskog udruženja infektologa i kliničkih mikrobiologa (Trainee Association of ESCMID - TAE)

4. 2017-2020, Podpredsednik za mlade Evropskog udruženja rinologa (European Rhinology Society/ERS)

**Rukovođenje ili angažovanje u nacionalnim ili međunarodnim naučnim ili stručnim organizacijama**

1. 2024 – u toku, član radne grupe Ministarstva za Nauku Republike Srbije za formiranje strategije za nauku za naredni 5-godišnji period

2. 2022 – 2025, član Radne grupe Evropskog udruženja za medicinsku mikologiju za pisanje vodiča za dijagnostiku i lečenje kandidijaze (ECMM-ISHAM Candidiasis 2022 Guideline)

3. 2022 – u toku član Radne grupe za pneumoniju Evropskog udruženja za respiratornu medicinu (European Respiratory Society/ERS) »ERS Task Force: Development of a core outcome set for trials evaluating the management of pneumonia (COSPneumonia)«

4. 2021 – u toku, Član Radnog tela za Otvorenu nauku Ministarstva za nauku i tehnološki razvoj Republike Srbije

5.2020 – u toku, član naučnog odbora za recenziju naučno-istraživačkih projekata Belgijskog Fonda za nauku (The Research Foundation – FWO; član ekspertskog panela - MED8RP Health Sciences)

6. 2022 – u toku, Sudija Suda časti Lekarske komore Srbije

7. 2021 – u toku, član radne grupe za Otvorenu nauku Ministarstva za nauku Republike Srbije.

8. 2020 – u toku, veštak za infektivne bolesti Instituta za Sudsku medicinu, MFUB, Beograd

9. 2020 – u toku, Član medicinskog tima upravnog odbora UEFA (The Union of European Football Associations)

10. 2020 – u toku, Član Upravnog odbora etičkog komiteta (ESCMID Ethics Advisory Committee) Evropskog udruženja infektologa i kliničkih mikrobiologa (European Society for Clinical Microbiology and Infectious Diseases/ESCMID)

11. 2020 – u toku, Član Ekspertske grupe Evropskog udruženja infektologa za pisanje zvaničnih smernnica za lečenje KOVID-19 (ESCMID COVID-19 Treatment Guidelines Committee)

12. 2020 – Tokom pandemije COVID-19 - član radne grupe za pisanje Nacionalnog vodiča za lečenje KOVID-19.

13. 2019 –u toku, Član upravnog odbora UNESCO za otvorenu nauku (UNESCO Open Science Advisory Committee)

14. 2019 – u toku, Član upravnog odbora za mlade Međunarodnog udruženja za gljivične infekcije (International Society of Human and Animal Medicine/ISHAM)

15.2019 – u toku, Recenzent za projekte Evropskog udruženja infektologa i kliničkih mikrobiologa (European Society for Clinical Microbiology and Infectious Diseases/ESCMID)

16. 2018 – 2020, Recenzent projekata Italijanskog ministarstva za nauku (Italian Ministry of Education, University and Research)

17. 2018 – 2020, Recenzent Italijanskog ministarstva za nauku, oblast Medicinskih nauka (REPRISE research founding Italian Ministry of Education, University and Research)

18. 2018 – 2021, Član ESCMID Professional Affairs Committee (European Society for Clinical Microbiology and Infectious Diseases/ESCMID)

19. 2018 – u toku, Član upravnog odbora ISID Emerging Leaders (International Society for Infectious Diseases/ISID)

20. 2017 – 2018, Recenzent projekata Italijanskog ministarstva za nauku, oblast Medicinskih nauka (PRIN 2017 Italian Ministry of Education, University and Research)

21. 2017 – u toku, Recenzent za projekte Evropske Unije RESPIRE3 Marie Sklodowska-Curie

22. 2017 – u toku, Recenzent za projekte Evropskog Respitornog udruženja (European Respiratory Society (ERS) Research Fellowships)

23. 2017 – u toku, Član upravnog odbora Međunarodnog udruženja infektologa (Council member of International Society for Infectious Diseases/ISID)

24. 2017 – u toku, Član Ekspertskog tima Evropskog Respitornog udruženja (European Respiratory Society/ERS College of Experts)

25. 2017 – u toku, Član Evropskog borda za akreditaciju pulmoloških kurseva (ERS European Board for Accreditation in Pneumology / EBAP)

26. 2016 – 2019, Član Upravnog odbora i Blagajnik Udruženja za Alergologiju i Kliničku Imunologiju (UAKIS)

27. 2016 – toku, Član međunarodnog odbora za Doktorske akademske studije (International PhD Board member, University of Sassari, Sardinia, Italy)

28. 2016 – u toku, Saradnik na projektu “Global Burden of Disease”, Institute for Health Metrics and Evaluation, University of Washington, USA.

29. 2009 – 2015. sekretar i član Upravnog odbora „Društva medicinskih mikologa Srbije" (DMMS)

**Rukovođenje ili angažovanje u nacionalnim ili međunarodnim institucijama od javnog značaja**

- Član je ekspertskog panela „MED8RP Health Sciences“ za Doktorske disertacije i recenzije naučno istraživačkih projekata Belgijskog Fonda za nauku (The Research Foundation – FWO)

- Član je ekspertskog panela za recenzije naučno-istraživačkih projekata Španskog Fonda za nauku (”La Caixa” Foundation)

- Sudija je Suda časti Lekarske komore Srbije

- Član je radne grupe za Otvorenu nauku Ministarstva za nauku Republike Srbije

- Član je međunarodnog odbora za Doktorske akademske studije Univerziteta u Sasariju, Italija (International PhD Board member, University of Sassari, Sardinia, Italy)

**Saradnja sa drugim visokoskolskim, naucno-istrazivackim ustanovama u zemlji i inostranstvu – mobilnost**

**- Predavanja po pozivu ili plenarna predavanja na medjunarodnim akreditovanim skupovima u zemlji i inostranstvu**

Dr Barać je održala 40 predavanja po pozivu:

IYBSSD 2022. Barac A. A simple and low cost tetra-primer ARMS-PCR method for detection triazole-resistant Aspergillus fumigatus (L’Oréal-UNESCO awardee for Women in Science). SANU, Beograd, Srbija

2022. Barac A. Antibiotic therapy of SSTI. ESCMID Postgraduate Education Course “Clinical microbiology testing in settings with limited resources and high prevalence of AMR: the role of diagnostic stewardship” Šibenik, Hrvatska

13.05.2022. Barac A. Invazivna aspergiloza - dijagnoza i terapija (mesto amfotericina B). KME „HOBP i Astma - pravi izbor terapije“, online.

23.04.2022. Barac A. Ethical issues in infectious diseases. ECCMID 2022, Lisbon, Portugal

07.04.2022. Barac A. Fungal Sinusitis in Post COVID-19 Patients. 3rd Balkan Rhino Forum. Athens, Greece.

28.03.2022. Barac A. Presentation of European Society of Clinical Microbiology and Infectious Diseases (ESCMID) COVID-19 treatment guidelines and comparison with Serbian national guidelines for COVID-19. The first World Conference fighting COVID-19, Beograd, Srbija.

09.10.2021. Barac A. Diagnostic Value of Galactomannan in Bronchoalveolar Lavage Fluid for Chronic Respiratory Disease with Pulmonary Aspergillosis. TIMM-10, Aberdeen, UK

29.09.2021. Barac A. Overlooked Treatments of rhinitis/rhinosinusitis with Herbal Medicine.  
ERS-ISIAN 2021, Thessaloniki, Greece.

24.06.2021. Barac A. Maternity Break and Its Impacts in the Career of Young Scientists. „Early-Career Women in Science: Current Challenges and How to Overcome Them“. World Microbe Forum 2021, online.

07.05.2021. Barac A. Dijagnoza i lečenje alergijskog gljivičnog rinosinusitisa. IV Kongres alergologa i kliničkih imunologa Srbije (UAKIS) sa međunarodnim učešćem “Interdisciplinarne teme u alergologiji i kliičkoj imunologiji“, Beograd, Srbija.

29.09.2019. Barac A. Angioinvasive rhinocerebral and pulmonary mucormycosis. ERS 2019. Madrid, Spain.

01.07.2019. Barac A. What we should know about the role of fungal infection in chronic rhinosinusitis? The Congress of European ORL-HNS, Brussels, Belgium

02.07.2019. Barac A. Fungi-Induced Upper and Lower Respiratory Tract Allergic Diseases. 5th Congress of European ORL-HNS, Brussels, Belgium

02.06.2019. Barac A. Biologicals and personalized medicine: a new hope for chronic rhinosinusitis. EAACI, Lisbon, Portugal

04.04.2019. Barac A. Upper-respiratory tract diseases: host-microbe interactions in chronic rhinosinusitis. 2nd Balkan Rhino-Forum, Beograd, Srbija

10.03.2019. Barac A. Alergijska oboljenja gornjih i donjih partija disajnih puteva uzrokovana gljivama: jedna bolest ili odvojeni entiteti? Alergološki simpozijum „Prof. dr Vladimir Spužić“, Beograd, Srbija

02.11.2018. Barac A. Primena vorikonazola u lečenju infekcija izazvanih gljivama roda Aspergillus: problem rezistencije, potreba za nadzorom i mere prevencije. Sekcija Infektologa SLD „Novine u antimikrobnoj terapiji“, Borsko Jezero, Srbija.

01.10.2018. Barac A. Controversies in use of corticosteroids in the treatment of fungal rhinosinusitis.

Serbian International ENT Congress, Beograd, Srbija

23.07.2018. Barac A. Fungal infections of the ear nose and throat. Evidence of the role of fungi in the

pathogenesis of sinonasal polyposis. Visiting Professor, Department for Oto-Rhino-Laryngology, University of Sassari, Sardinia, Italy

11.07.2018. Barac A. Interesting Clinical Cases: What we have learned from clinical practice? Visiting

Professor, Department for Biomedicine, University of Sassari, Sardinia, Italy

09.07.2018. Barac A. Fungal infections: a spectrum of diseases. Visiting Professor, Department for

Biomedicine, University of Sassari, Sardinia, Italy

30.06.2018. Barac A. PubMed vs social media in research ERS-ISIAN 2018 congress, London, UK

26.04.2018. Barac A. Rhinitis is not CRS; why does it matter? ERS-ISIAN 2018 congress, London, UK 21.04.2018. Barac A. Fungal rhinosinusitis: innovations in diagnosis and its implication for clinical practice. 57th ENT Week, Beograd, Srbija

17.03.2018. Barac A. Gljivične infekcije respiratornog trakta: dijagnostika i lečenje. Sekcija Infektologa SLD „Prikaz slučajeva iz kliničke prakse infektologa“, Beograd, Srbija

16.03.2018. Barac A. Use of natural substances in the treatment of fungal rhinosinusitis. 2st Serbian

Rhinologic Congress; 3nd RAAS Symposium. Beograd, Srbija

01.03.2018. Barac A. Rare case of fulminant angioinvasive rhinocerebral mucormycosis. 18th International Congress on Infectious Diseases, Buenos Aires, Argentina, Barac A. Prevention of tuberculosis: clinical aspects of the disease, TB prevalence. TBnet Academy, Yerevan, Armenia

31.10.2017. Barac A. Reliable vs. unreliable sources for research. 4th European Congress ORL-NHS, Cornerstones in European ORL-NHS, Barcelona, Spain

11.10.2017. Barac A. Use of moxifloxacin in the treatment of acute bacterial rhinosinusitis. 1st Serbian Rhinologic Congress; 2nd RAAS Symposium. Beograd, Srbija

15.05.2017. Barac A. Eradication of fungi from sinuses helps in improvement of lower respiratory tract’s clinical symptoms in children with cystic fibrosis. 20th Congress of International Society for Human and Animal Mycology, Young-ISHAM day, Amsterdam, Netherlands

01.04.2017. Barac A. Fungal rhinosinusitis: New trends in diagnostics and treatment. 1st Serbian Rhinologic Congress; 2nd RAAS Symposium. Beograd, Srbija

17.10.2016. Barac A. Diagnosis and treatment of fungal infections in oncology patients. International medical congress, Tirana, Albania

06.07.2016. Barac A. The fungi on sinonasal mucosa: normal content or silent threat? ERS-ISIAN 2016

congress, Stockholm, Sweden

12.05.2016. Barac A. Allergic fungal rhinosinusitis: new trends in diagnostics and treatment. Serbian

Medical Society/SLD, Allergology section, Beograd, Srbija

16.02.2016. Barac A. Are the fungi hidden threat? Faculty of Medicine, University of Tel Aviv, Tel Aviv, Israel

19.10.2015. Barac A. Diagnosis of invasive fungal diseases. Public Health of England, London, UK.

01.10.2015. Barac A. Role of fungi and diagnostic of invasive fungal infections in febrile neutropenia. 7th Eurasia congress of infectious diseases (EACID), Tbilisi, Georgia

05.06.2015. Barac A. Chronic rhinosinusitis - association of recalcitrant nasal polyposis and fungal finding in polyp’s single-cell suspension. ISC Congress, Graz, Austria

22.02.2014. Barac A. Rhino-cerеbral mucormycoses – new aspects in diagnosis and treatment. WiBioSe International Conference, Beograd, Srbija

20.09.2013. Barac A. Invasive rhino-cerebral mucormycosis at patients with neoplasm in Serbia - report of two cases. Days of Preventive Medicine in Nis, Nis, Serbia

15.12.2012. Barac A. Allergic fungal sinusitis - new aspects in diagnosis and therapy. 41st Symposium of innovations in medicine, School of Medicine, University of Belgrade, Beograd, Srbija

**Stečeno zvanje gostujućeg profesora**

Dr Barać je Gostujući Profesor (Visiting Professor) od 2016 god. na Univerzitetu u Sasariju, Italija.

**2. Kandidat dr ANKICA VUJOVIĆ, doktor medicinskih nauka, specijalista infektologije**

**A.OSNOVNI BIOGRAFSKI PODACI**

–Ime, srednje ime i prezime: Ankica (Milenko) Vujović (devojačko prezime Bjelić)

–Datum i mesto rođenja: 16.05.1988. Beograd, Srbija

–Ustanova gde je zaposlen: Klinika za infektivne i tropske bolesti UKCS

–Zvanje / radno mesto: Lekar specijalista infektolog

–Naučna oblast: Infektivne bolesti

**B. STRUČNA BIOGRAFIJA, DIPLOME I ZVANJA**

**Osnovne studije**

–Naziv ustanove: Medicinski fakultet u Beogradu

–Mesto i godina završetka, prosečna ocena: Beograd, 2015. godina, prosečna ocena 9,00

**Doktorske studije**

* Naziv ustanove: Medicnski fakultet Univerziteta u Beogradu
* Mesto i godina odbrane i članovi komisije: Beograd,2024.godine, članovi komisije: Prof.dr Miloš Korać, prof. dr Dušan Popadić, prof. dr Aleksandar Klašnja
* Mentori: Prof. dr Ivana Milošević, prof. dr Marina Đelić
* Naslov disertacije: „Prognostički značaj koncentracije citokina osovine IL-23/17 u napredovanju fibroze jetre kod bolesnika sa hroničnim hepatitisom C i nealkoholnim steatohepatitisom“,
* Uža naučna oblast: Fiziološke nauke

**Specijalizacija**

* Naziv: Infektologija
* Medicinski fakultet Univerziteta u Beogradu, Infektivne bolesti
* Mesto i godina završetka, ocena i članovi komisije: Medicinski fakultet, Univerzitet u Beogradu, ocena 5, članovi komisije: Prof. dr Miloš Korać, prof.dr Ivana Milošević, prof.dr Branko Milošević.

**Uža specijalizacija**

* Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu
* Mesto, godina završetka i članovi komisije- u toku
* Naslov rada uže specijalizacije: Nije određen
* Uža naučna oblast: Klinička farmakologija

**Dosadašnji izbori u nastavna i naučna zvanja**

* 2018.godine izabrana je u zvanje Istraživač pripravnik u oblasti Fiziološke nauke
* 2019.godine Istraživač saradnik u oblasti Fiziološke nauke
* 2022.godine izabrana je u zvanje Kliničkog asistenta na Medicinskom fakultetu Univerziteta u Beogradu, na predmetu Infektivne bolesti.

**V. OCENA O REZULTATIMA PEDAGOŠKOG RADA**

**Osnovna nastava**

Dr Ankica Vujović je od 2022. god., angažovana kao klinički asistent u izvođenju: praktične nastave iz oblasti infektivnih bolesti za studente na osnovnim studijama Medicinskog fakulteta Univerziteta u Beogradu, sa punim fondom časova predviđenim za nastavni program. Kao klinički asistent dr Ankica Vujović učestvuje i u izvođenju praktične nastave za studente Osnovnih akademskih studija sestrinstva. Dr Ankica Vujović je tokom četiri godine učestvovala u nastavi za studente medicine u okviru studija kao demonstrator na predmetu Medicinska fiziologija. Od strane studenata nije ocenjena za školsku 2022/2023. i 2023/2024.god., zbog porodiljskog odsustva u tom periodu.

**Nastava na engleskom jeziku**

Dr Ankica Vujović učestvuje u izvođenju praktične nastave za studente osnovnih studija, nastave na engleskom jeziku po predviđenom planu u proteklom periodu.

**Poslediplomska nastava**

Učestvovala je u izvođenju nastave Master akademskih studija fizičke aktivnost, zdravlje i terapija vežbanjem na Medicinskog fakulteta Univerziteta u Beogradu tokom školske 2023/2024 god. Sve vreme učestvuje i u stručnom usavršavanju specijalizanata Infektivnih bolesti prenoseći im svoja klinička znanja tokom boravka na odeljenjima Infektivne klinike.

**G. OCENA REZULTATA U OBEZBEĐIVANJU NAUČNO-NASTAVNOG PODMLATKA**

Mentor je studentkog radaIntegrisanih akademskih studija, Medicinskog fakulteta u Beogradu - Branko Beronja (387/18), rad pod nazivom: “Prospektivno multicentrično ispitivanje efekata tocilizumaba u lečenju kovida-19: dvogodišnje praćenje”, Kongres studenata biomedicinskih nauka, Kopaonik 2024.godine. Dr Ankica Vujović je svojim kontinuranim radom u Laboratotriji za medicinu sporta i terapiju vežbanja, kao i na Klinici za infektivne i tropske bolesti UKCS, nesebično prenosila znanje i veštine u naučno-istraživačkom radu studentima svih nivoa studija studija na MFUB.

**D. NAUČNI I STRUČNI RAD**

**a) Spisak objavljenih naučnih i stručnih radova**

**ORIGINALNI RADOVI INEXTENSO U ČASOPISIMA SA JCR (JOURNAL CITATION REPORTS) LISTE:**

1. Gmizic I, Barac A, Todorovic N, Sabanovic M, Kekic N, Boskovic N, **Vujovic A**, Nikolic N, Knezevic N, Milosevic I, Stevanovic G. Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study. J Infect Dev Ctries. 2024;18(5):694-700. **M23 IF 1,5.**
2. Barac A, **Vujovic A**, Peric J, Tulic I, Stojanovic M, Stjepanovic M. Rethinking Aspergillosis in the Era of Microbiota and Mycobiota. Mycopathologia. 2024;189(4):49. **M22 IF 3,2**.
3. Barac A, **Vujovic A**, Drazic A, Stevanovic G, Paglietti B, Lukic K, Stojanovic M, Stjepanovic M. Diagnosis of Chronic Pulmonary Aspergillosis: Clinical, Radiological or Laboratory? J Fungi (Basel). 2023;9(11):1084. **M21 IF 4,5.**
4. Gauffin O, Brand JS, Vidlin SH, Sartori D, Asikainen S, Català M, Chalabi E, Dedman D, Danilovic A, Duarte-Salles T, García Morales MT, Hiltunen S, Jödicke AM, Lazarevic M, Mayer MA, Miladinovic J, Mitchell J, Pistillo A, Ramírez-Anguita JM, Reyes C, Rudolph A, Sandberg L, Savage R, Schuemie M, Spasic D, Trinh NTH, Veljkovic N, **Vujovic A**, de Wilde M, Zekarias A, Rijnbeek P, Ryan P, Prieto-Alhambra D, Norén GN. Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study. Drug Saf. 2023;46(12):1335-1352. **M21 IF 4,1.**
5. **Vujovic A**, Isakovic AM, Misirlic-Dencic S, Juloski J, Mirkovic M, Cirkovic A, Djelic M, Milošević I. IL-23/IL-17 Axis in Chronic Hepatitis C and Non-Alcoholic Steatohepatitis-New Insight into Immunohepatotoxicity of Different Chronic Liver Diseases. Int J Mol Sci. 2023;24(15):12483. **M21 IF 5,6.**
6. Mitrovic N, Sabanovic M, **Vujovic A**, Jovanovic J, Nikolic N, Jug M, Todorovic N, Filipovic A, Milosevic I. Influence of chronic liver diseases on the course and outcome of COVID-19. PLoS One. 2023;18(7):e0288350. **M22 IF 3,3.**
7. Milošević I, Barać A, Jovanović J, **Vujović A**, Stevanović G, Todorović N, Milošević B. A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia. Trans R Soc Trop Med Hyg. 2023;117(9):668-672. **M22 IF 1,9.**
8. Despotovic A, Milosevic B, Cirkovic A, **Vujovic A**, Cucanic K, Cucanic T, Stevanovic G. The Impact of COVID-19 on the Profile of Hospital-Acquired Infections in Adult Intensive Care Units. Antibiotics-Basel. 2021;10(10):1146. doi: 10.3390/antibiotics10101146. **M21**; **IF 5,396.**
9. Milosevic I, Russo E, **Vujovic A**, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World Journal Gastroenterol. 2021;27(33):5488-5501. **M22 IF 5,715.**
10. Korać M, Rupnik M, Nikolić N, Jovanović M, Tošić T, Malinić J, Mitrović N, Marković M, **Vujović A**, Peruničić S, Bojović K, Djordjević V, Barać A, Milošević I. Clostridioides difficile ribotype distribution in a large teaching hospital in Serbia. Gut Pathology. 2020;12:26. **M22 IF 4,524**.
11. Milosevic I, **Vujovic A**, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. International Journal Molecular Science. 2019; 20(2):395. **M21 IF 4,653**.
12. Durmic T, Djelic M, Gavrilovic T, Antic M, Jeremic R, **Vujovic A**, Mihailovic Z, Zdravkovic M. Usefulness of heart rate recovery parameters to monitor cardiovascular adaptation in elite athletes: The impact of the type of sport. Physiology international. 2019; 106 (1): 81-94. **M23 IF 1,410**.

**RAD U ČASOPISU MEDICINSKA ISTRAŽIVANjA**

1. Mitrović N, Nikolić N, Filipović A, **Vujović** *A*, Karić U, Šabanović M, Milošević I. The impact of chronic viral hepatitis on COVID-19: cinical course and risk factors for poor outcome. Medicinska istraživanja 2024; 57(2); 65-73.
2. Barać A, Despotovic A, **Vujovic A**, Cucanic T, Cucanic K, Mitic A, Stjepanovic M Maric N, Filipovic A, Vlaskovic J, Knezevic N, Stojanovic M, Micic J, Stevanovic G. Differences in clinical and laboratory characteristics in patients infected with COVID-19 during different epidemic waves. Medicinska istraživanja 2023; 56(4):1-9.

**CEO RAD U ČASOPISU KOJI NIJE UKLJUČEN U GORE POMENUTE BAZE PODATAKA**

1. **Vujović A**, Milošević I, Đelić Marina. Uticaj imunološkog odgovora na razvoj fibroze kod hroničnih bolesti jetre različite etiologije. Medicinski podmladak. 2024;76(2), doi:10.5937/mp76-48987.
2. **Vujović A**, Stevanović G, Milošević B, Barać A, Despotović A, Jug M, Milošević I. Uticaj COVID-19 pandemije na razvoj amtimikrobne rezistencije. Svet rada (naučni časopis za pitanja bezbednosti i zdravlja na radu, medicine rada i zaštite životne sredine za jugoistočnu Evropu), 2022; 19(3): 273-336.
3. Milosevic I, **Vujovic A**. COVID-19: What have we learned since the beginning of the epidemic until today? Serbian Journal of the Medical Chamber. 2021; 2(3): 248-65. doi.org/10.5937/smclk2-32959.
4. Jeremić R, **Bjelić A**, Skorupan N. Metabolički odgovor na test fizičkog opterećenja kod fizički aktivnih i neaktivnih ispitanika. Medicinski podmladak. 2012; 63(1-2): 74-77.

**IZVOD U ZBORNIKU MEĐUNARODNOG SKUPA**

1. **Vujović A**, Isaković A, Misirlić-Denčić S, Ćirković A, Stevanović G, Barać A, Milišević I, Đelić M. Correlation between biochemical/virological and immunological parameters in chronic hepatitis C. Journal of IMAB. Belgrade, Serbia. 2023 October 12-15. Abstract book, p. 34-37.
2. **Vujović A**, Stevanović G, Milošević B, Despotović A, Barać A. Changing profile of intrahospital infections during the COVID-19 pandemic in Intensive Care Units - are we in danger of entering the pre-antibiotic era? EMERGING INFECTIOUS DISEASES:Are we ready for new evolutionary challenges? Belgrade, Serbia. 2023 March 30-April 1. Abstract book, p. 97-99.
3. Milosevic I, **Vujovic A,** Stevanovic G, Jovanovic J, Milosevic B, Barac A. Effectiveness of the tocilizumab treatment in COVID‐19: A single center experience. The First World Conference Fighting COVID-19 Pandemic Health Challenges. Belgrade, Serbia. 2022 March 26-28. Abstract book in press.
4. Djelic M, Mazic S, Sumarac Dumanovic M, Jeremic R, **Vujovic A,** Durmic T, Cvetkovic S, Micic D. Impact of exercise training on insulin sensitivity estimated by HOMA model in elite athletes: association with body composition. 19th European Congress of Endocrinology. Lisabon, Portugal. 2017 May 20–23. doi: 10.1530/endoabs.49.EP470.
5. Đelić M, Trajković V, Šumarac Dumanović M, Mazić S, Durmić T, Jeremić R, **Bjelić A,** Micić D. *Pro-inflammatory cytokines responses to acute exercise in athletes and sedentary controls: association with body composition and insulin.* 18th European Congress of Endocrinology. Munich, Germany. 2016 May 28 - 31. Abstract book, p. 378.
6. **Bjelić A**, Jeremić R**,** Đelić M. *Growth hormone response to acute exercise in elite male volleyball players*. Second International Student Congress. Graz, Austria. 2015 June 4-6. Abstract book, p. 105.
7. Jeremić R**,** Jeremić M, **Bjelić A**, Đelić M. *The relationship between body fat percentage and resting blood pressure in elite athletes.* Second International Student Congress. Graz, Austria. 2015 June 4-6. Abstract book, p. 66.
8. **Bjelić A**, Jeremić R. *Free fatty acid level response to high-intensity acute exercise in athletes with different body composition*. First Global Students’ Conference of Biomedical Sciences. Belgrade, Serbia. 2014 October 2 – 5. Abstract book, p. 62.
9. Jeremić R, **Bjelić A**, Jeremić M. *Leptin response to high-intensity acute exercise in athletes with different body composition*. First Global Students’ Conference of Biomedical Sciences. Belgrade, Serbia. 2014 October 2 – 5. Abstract book, p. 63.
10. Jeremić R, Jeremić M, **Bjelić A**. *Effects of acute high-intensity exercise on plasma IL-17 concentration in elite athletes*. 9th Young European Scientist Meeting. Porto, Portugal. 2014 September 18 – 21. Abstract book, CD, p. 56.
11. Jeremić R, Jeremić M, **Bjelić A**, Rogač Ž. *Growth hormone and fatty acid response to acute exercise in elite male athletes.* XIII International Congress of Medical Sciences. Sofia, Bulgaria. 2014 May 8 – 11. Abstract book, p. 118. Supplement to issue I/2014, Tribuna mediva LXVI.
12. Jeremić R, **Bjelić A**. *Adipocytokines profile in elite athletes with different body composition: a comparison of volleyball players, water polo players and controls.* 24th European Students' Conference. Berlin, Germany. 2013 September 4 – 7. Abstract book, p. 117.

**IZVOD U ZBORNIKU NACIONALNOG SKUPA**

1. **Vujović A,** Gmizić I, Kanački I, Nikolić N, Marković A, Milošević I, Korać M. *Malapsorpcioni sindrom kod pacijenata sa C.difficile infekcijom*. 4. Kongres infektologa Srbije sa međunarodnim učešćem. Kopaonik, 5-8. oktobar 2017. Knjiga sažetaka, str. 13.
2. **Bjelić A**,Jeremić R. *Nivo leptina kod fizički aktivnih i neaktivnih osoba sa različitim procentom telesnih masti.* 56. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Vrnjačka Banja, 24 - 28. april 2015. godine. Knjiga sažetaka, CD, str. 662.
3. Jeremić R, **Bjelić A**, Adžić N. *Nivo proinflamatornih citokina kod fizički aktivnih ispitanika i sedentarne kontrole: povezanost sa telesnom kompozicijom i insulinskom senzitivnošću.* 56. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Vrnjačka Banja, 24 - 28. april 2015. godine. Knjiga sažetaka, CD, str. 674.
4. **Bjelić A**,Jeremić R. *Povezanost nivoa adipocitokina i telesne kompozicije kod vrhunskih sportista.* 55. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Vrnjačka Banja, 26 - 30. april 2014. godine. Knjiga sažetaka, CD, str. 708.
5. Jeremić R, **Bjelić A**. *Pozitivan uticaj nivoa adiponektina na remodulaciju srca kod vrhunskih sportista.* 55. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Vrnjačka Banja, 26 - 30. april 2014. godine. Knjiga sažetaka, CD, str. 720.
6. **Bjelić A**, Jeremić R. *Odgovor proinflamatornih citokina na test fizičkog opterećenja kod fizički aktivnih i neaktivnih ispitanika.* 54. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Kopaonik, 28. april - 02. maj 2013. godine. Knjiga sažetaka, str. 406.
7. Jeremić R, **Bjelić A**. *Učestalost elektofizioloških promena karakterističnih za sportsko srce kod vrhunskih sportista.* 54. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Kopaonik, 28. april - 02. maj 2013. godine. Knjiga sažetaka, str. 421.
8. **Bjelić A**, Berisavac J,Jeremić R. *Odgovor hipotalamus-hipofiza-nadbubreg osovine na test fizičkog opterećenja kod fizički aktivnih i neaktivnih ispitanika.*53. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Kopaonik, 26 - 30. april 2012. godine. Knjiga sažetaka, str. 124.
9. Jeremić R, **Bjelić A**, Skorupan N. *Metabolički odgovor na test fizičkog opterećenja kod fizički aktivnih i neaktivnih ispitanika.*53. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem. Kopaonik, 26 - 30. april 2012. godine. Knjiga sažetaka, str. 136.

**b) Učešće na projektima**

1. U periodu od avgusta 2018. do kraja maja 2019.godine bila je angažovana kao Istraživač pripravnik, a potom kao Istraživač saradnik pri projektuMinistarstva prosvete, nauke i tehnološkog razvoja pod nazivom »Modulacija signalnih puteva koji kontrolišu intracelularni energetski balans u terapiji tumora i neuro-imuno-endokrinih poremećaja”, brojprojekta 41025.

**c) Citiranost**

Prema podacima sa Kobsona, radovi sa JCR liste u kojima je kandidat dr Ankica Vujović bila autor ili koautor citirani su u 420 navrata, H-index 5.

**Đ. OCENA O REZULTATIMA NAUČNOG I ISTRAŽIVAČKOG RADA**

Dr Ankica Vujović je uz ostalu dokumentaciju priložila spisak i fotokopije svih navedenih radova. Navedeno je ukupno 39 publikacija i to 18 radova objavljenih *in extenso* i 21 izvod. Od navedenih radova, 12 je sa JCR liste, 2 rada u časopisu Medicinska istraživanja i 4 rada u koja nisu indeksirana u gore navedenim bazama podataka. Ukupan IF u objavljenim radovima je 44,6. Pored navedenog, objavila je 12 izvoda u zbornicima međunarodnog skupa i 9 izvoda u zbornicima nacionalnog skupa.

Kandidat dr Ankica Vujović pokazuje kontinuitet u bavljenju naučnoistraživačkim radom od perioda osnovnih akademskih studija koji je nastavljen po zaposlenju u Klinici za infektivne i tropske bolesti UKCS, a svoje naučno interesovanje potvrdila je i izborom u načno zvanje Istraživača pripravnika, a potom i saradnika. Na osnovu priloženih publikacija može se zaključiti da se kandidat dr Ankica Vujović do sada bavila različitim oblastima infektologije. U izradi svoje doktorske disertacije koju je odbranila 30.09.2024. godine, bavila se imunološkim aspektima hepatitisa C. Pored toga pokazala je interesovanje u oblastima vezanim za dijagnostiku i lečenje C. difficile infekcije, kao i interesovanje u oblasti dijagnostike i lečenja intrahospitalnih infekcija. Učešćem u gore navedenom međunarodnom projektu je pokazala interesovanje u oblasti arbovirusnih infekcija, dok je učešćem u navedenoj multicentričnoj međunarodnoj studiji pokazala interesovanje u istraživanju efekta novog oralnog karbapenema za lečenje multirezistentnih bakterisjkih urinarnih infekcija. Aktuelno se bavi istraživanjem imunološkog odgovora u sepsi različite etiologije. Pored navedenog, kandidat dr Ankica Vujović je svoju naučnoistraživačku sposobnost potvrdila i time što je pomoćni urednik u časopisu “The Journal of Infection in Developing Countries“. U svemu navedenom se ogleda svestranost kadidata u velikom broju naučnih oblasti infektologije.

**E. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE**

Dr Ankica Vujović savesno i odgovorno učestvuje u radu i izvođenju nastavnih aktivnosti na Medicinskom fakultetu Univerziteta u Beogradu. Dr Ankica Vujvić je u periodu svog izbora u zvanje kliničkog asistenta pokazala veliku motivisanost da na zanimljiv način uvodi studente u sve aspekte infektivnih bolesti kroz praktičnu nastavu na srpskom i engleskom jeziku.

**Stručno-profesionalni doprinos**

Radi u odeljenju Kliničke farmakoterapije Klinike za infektivne i tropske bolesti, UKCS i deo je tima za lečenje nejasnih febrilnih stanja, septičnih stanja različite etiologije. Svakodnevno učestvuje u radu ambulante navedenog odeljenja. Angažovana je u sprovođenju dijagnostičkih procedura poput lumbalne punkcije, a radeći i kao deo tima Odeljenja za intenzivno lečenje angažovan je i u terapijskim procedurama intubacije i invazivne mehaničke ventilacije kritično obolelih pacijenata. Pored pomenutog, dr Ankica Vujović aktivno učestvuje i u lečenju bolesnika sa ostalim infektivnim i tropskim bolestima. Od izutente važnosti je period velikih izazova Infektivne klinike tokom Pandemije COVID-19, kada je studentima i tokom letnje prakse približila nove pristupe u lečenju infektivnih bolesti i to na prepoznatljiv dinamičan i zanimljiv način, uz mnogo kliničkih primera i praktičnih demonstracija u kojima aktivno učestvuju i studenti i pacijenti. Svoja saznanja i iskustva sveobuhvatno i na interesantan način prenosi poslediplomcima i specijalizantima. U svakodnevnom radu daje značajan doprinos u razvoju nastave iz infektivnih bolesti učestvovanjem u pisanju različitih tekstova koji će biti sadržani u novom udžbeniku Infektivnih bolesti.

**Doprinos akademskoj i široj zajednici**

Član je Srpskog lekarskog društva, Sekcije infektologa, Udruženja infektologa Srbije, kao i Srpskog udruženja za antimikrobnu hemioterapiju.

**Saradnja sa drugim visokoškolskim, naučnoistraživačkim ustanovama u zemlji i inostranstvu**

Dr Ankica Vujović, kao deo stručnog usavršavanja, učestvivala u studiji Oxford Univerziteta pod nazivom: EHDEN - Pharmacovigilance study-a-thon, Upsala, Švedska 2022.godina.

Dr Ankica Vujović održala je dva predavanja po pozivu na nacionalnom skupu:

1. Gostujući predavač- Lekarska Komora Srbije, Nacionalni kongres sa međunarodnim učešćem. “Infekcije kod imunosuprimiranih-problemi prepoznavanja, dijagnostikje I lečenja”. April 2024.godine.

2. Gostujući predavač - Srpsko lekarsko društvo. Sekcija za infektivne bolesti. Sekcija za istoriju medicine. “Dani sećanja na medicinara Luku Subotića”. Predavanje na temu: Malabsorbcioni sindrom u C. difficile infekciji. Decembar 2017.godine.

Takođe jedno na akreditovanom međunarodnom skupu:

1.ESCMID Antimicrobial Stewardship. Predavanje na temu: Using “clinical decision support software” to facilitate stewardship interventions and tracking outcomes. Novembar 2022.godine.

**3. Kandidat dr BORIS JEGOROVIĆ, doktor medicinskih nauka, specijalista infektologije**

**A.** **OSNOVNI BIOGRAFSKI PODACI**

– Ime, srednje ime i prezime: Boris (Slobodanka) Jegorović

– Datum i mesto rođenja: 06.05.1987., Beograd, Srbija

– Ustanova gde je zaposlen: Klinika za infektivne i tropske bolesti, Univerzitetski klinički centar Srbije

– Zvanje/radno mesto: Lekar specijalista infektolog

– Naučna oblast: Infektivne bolesti

**B. STRUČNA BIOGRAFIJA, DIPLOME I ZVANJA**

**Osnovne studije**

– Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu

– Mesto i godina završetka: Beograd, 2012. godina, prosečna ocena 9,44

**Doktorske studije**

* Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu
* Mesto i godina odbrane i članovi komisije: Beograd, 2023. godine, članovi komisije: prof. dr Jadranka Maksimović, Prof. dr Goran Stevanović, Prof. dr Mirjana Bećarević
* Mentori: prof. dr Sandra Šipetić Grujičić, prof. dr Svetlana Ignjatović
* Naziv doktorske disertacije: "Procena značaja serumskog amiloida A i drugih reaktanata akutne faze kod SARS-CoV-2 infekcije na težinu kliničke slike, hospitalizaciju i smrtni ishod"
* Uža naučna oblast: Epidemiologija

**Specijalizacija**

– Naziv: Infektologija

Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu, Infektivne bolesti

– Mesto i godina završetka, ocena i članovi komisije: Medicinski fakultet, Univerzitet u Beogradu, 2021. godina, ocena 5, članovi komisije: prof. dr Jovan Ranin, doc. dr Jasmina Poluga, doc. dr Ksenija Bojović

**Uža specijalizacija**

– Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu

– Mesto, godina završetka i članovi komisije: U toku.

– Naslov rada uže specijalizacije: Nije određen.

– Uža naučna oblast: Nefrologija

**Dosadašnji izbori u nastavna i naučna zvanja**

– 2022. godine izabran je u zvanje Kliničkog asistenta na Medicinskom fakultetu Univerziteta u Beogradu, na predmetu Infektivne bolesti.

**V. OCENA O REZULTATIMA PEDAGOŠKOG RADA**

**Osnovna nastava**

Dr Boris Jegorović učestvuje u izvođenju nastave održavajući studentske vežbe redovne nastave na predmetu Infektivne bolesti Integrisanih akademskih studija medicine na Medicinskom fakultetu Univerziteta u Beogradu tokom sedmog i osmog semestra (240 časova godišnje), a za sticanje zvanja doktor medicine. Sarađivao je u više navrata sa Centrom za stručni i naučno-istraživački rad studenata, kao mentor i recenzent studentskih radova. . Prema izveštaju Centra za obezbeđivanje kvaliteta, unapređenje nastave i razvoj medicinske edukacije Medicinskog fakulteta Univerziteta u Beogradu ocenjen je od strane studenata ocenom 4,87 za školsku 2022/2023. godinu i ocenom 4,88 za školsku 2023/2024. godinu.

**Nastava na engleskom jeziku**

Dr Boris Jegorović učestvuje u izvođenju praktične nastave za studente osnovnih studija, nastave na engleskom jeziku po predviđenom planu u proteklom periodu.

**Poslediplomska nastava**

Dr Boris Jegorović učestvuje u stručnom usavršavanju specijalizanata Infektivnih bolesti prenoseći im svoja klinička znanja tokom boravka u odeljenjima Infektivne klinike.

**G. OCENA REZULTATA U OBEZBEĐIVANJU NAUČNO-NASTAVNOG PODMLATKA**

Dr Boris Jegorović je mentor jednog studentskog rada u sklopu Integrisanih akademskih studija, Medicinskog fakulteta u Beogradu – autor Ana Janković, rad pod nazivom ″Značaj određivanja inflamatornih parametara kod hospitalizovanih pacijenata sa *Clostridioides difficile* infekcijom″, Kongres studenata biomedicinskih nauka, Kopaonik 2024. godine. Trenutno je mentor još jednog studentskog rada koji je u izradi.

**D. NAUČNI I STRUČNI RAD**

**a) Spisak objavljenih naučnih i stručnih radova**

**ORIGINALNI RADOVI INEXTENSO U ČASOPISIMA SA JCR (JOURNAL CITATION REPORTS) LISTE:**

1. Nelson Z, Aslan AT, Beahm NP, Blyth M, Cappiello M, **Jegorović B**, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults. JAMA Netw. Open. 2024 Nov 4;7(11):e2444495–5. https://doi.org/10.1001/jamanetworkopen.2024.44495, **M21a, IF 10,5**
2. Spellberg B, Nielsen TB, Phillips MC, Ghanem B, Boyles T, **Jegorović B**, et al. Revisiting Diagnostics: ESR and CRP: It’s Time to Stop the Zombie Tests. Clin. Microbiol. Infect. 2024 Aug 1; https://doi.org/10.1016/j.cmi.2024.08.017, **M21a, IF 10,9**
3. Nikolić N, Poluga J, Milošević I, Todorović N, Filipović A, **Jegorović B**, et al. Neurological and neuromuscular manifestations in patients with West Nile neuroinvasive disease, Belgrade area, Serbia, season 2022. Neurol. Sci. 2023 Aug 22;45(2):719–26. https://doi.org/10.1007/s10072-023-07025-y, **M22, IF 2,7**
4. **Jegorovic B**, Nikolic A, Milinkovic N, Ignjatovic S, Sipetic Grujicic S. The utility of serum amyloid A and other acute-phase reactants determination in ambulatory COVID-19 patients. J. Med. Biochem. 2023 Mar 19;42(3).

https://doi.org/10.5937/jomb0-42799, **M23, IF 2,0**

1. **Jegorović B**, Milinković N, Sarić Matutinović M, Šipetić Grujičić S, Ignjatović S. Comparison of the ELISA method with the nephelometric method for determination of serum amyloid A in patients with COVID 19. Scand. J. Clin. Lab. Invest. 2022 Nov 30;83(1):1–4.

https://doi.org/10.1080/00365513.2022.2150983, **M23, IF 1,3**

1. Dimic J, **Jegorovic B**. Herpes zoster in an immunocompetent infant with a history of varicella in early infancy and after a minor injury – case report and literature review. Srp Arh Celok Lek. Online First, September 2021. https://doi.org/10.2298/SARH210610074D **M23, IF 0,207**
2. Delic S, Mijac V, Gajic I, Kekic D, Ranin L, **Jegorovic B**, Culic D, Cirkovic V, Siljic M, Stanojevic M, Paragi M, Markovic M, Opavski N. A Laboratory-Based Surveillance Study of Invasive Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae Diseases in a Serbian Pediatric Population—Implications for Vaccination. Diagnostics. 2021; 11(6):1059.

https://doi.org/10.3390/diagnostics11061059. **M21, IF 3,110**

1. Poluga J, Karić U, Dakić Z, Katanić N, Lavadinović L, Milošević B, Nikolić N, Urošević A, **Jegorović B**, Pavlović M. Severe imported malaria in a Serbian referral center. Vojnosanit Pregl 2019; 76(5): 470–475. doi.org/10.2298/VSP170509124P. **M23, IF 0,152**
2. Gajic I, Mijac V, Ranin L, Grego E, Kekic D, **Jegorovic B**, Smitran A, Popovic S, Opavski N. Changes in Macrolide Resistance Among Group A Streptococci in Serbia and Clonal Evolution of Resistant Isolates. Microbial drug resistance 2018; 24(9): 1326-1332. DOI: 10.1089/mdr.2017.0306. **M22, IF 2,344**
3. Erdem H, Inan A, Guven E…**Jegorović B**. et al. The burden and epidemiology of community-acquired central nervous system infections: a multinational study. Eur J Clin Microbiol Infect Dis 2017; 36: 1595–1611.doi.org/10.1007/s10096-017-2973-**0. M22, IF 2,543**
4. Ćirković I, Jovalekić M, **Jegorović B**. In Vitro Antibacterial Activity Of Garlic And Synergism Between Garlic And Antibacterial Drugs. Archives of Biological Sciences 2012; 64(4): 1369-1375. DOI:10.2298/ABS1200369C. **M23, IF 0,791**

**CEO RAD U ČASOPISU KOJI NIJE UKLJUČEN U GORE POMENUTE BAZE PODATAKA**

1. Karić U, Petković KA, **Jegorović B**, Šabanović M, Petković S, Katanić N, Poluga J. Tick-borne infections. Galenika Medical Journal. 2024;3(11):73-79.
2. **Jegorović B**, Šipetić-Grujičić S, Ignjatović S. Significance of serum amyloid A for the course and outcome of SARS-CoV-2 infection. Med podml. 2023 Jan 1;74(3):13–8.

https://doi.org/10.5937/mp74-42841

**RAD U ČASOPISU KOJI JE UKLJUČEN U BAZU PODATAKA MEDLINE**

1. Nikolić N, Jovanović J, Karić U, Ostojić I, **Jegorović B**, Marković M, Mitrović N, Milošević I, Milošević B. Kliničke karakteristike i faktori rizika za smrtni ishod kod bolesnika sa COVID-19 lečenih u jedinici intenzivne nege. Svet rada. 2022; 2:371-383.

**IZVOD U ZBORNIKU MEĐUNARODNOG SKUPA**

1. Nikolić N, Milošević B, Poluga J, Filipović A, Todorović N, Karić U, Mitrović N, **Jegorović B**, Milošević I. Acute flaccid paralysis in patients with West Nile neuroinvasive disease: clinical presentation and the disease outcome. 33rd European Congress of Clinical Microbiology and Infectious Disease, April 15-18, Copenhagen, Denmark 2023. – Abstract book
2. Korac M, Milosevic I, Malinic J, Popovic N, Mitrovic N, **Jegorovic B**. Diagnostic and therapeutic strategies in patients with Clostridium difficile infection. 6th Southeast European Conference of Chemotherapy and Infection, November, Thessaloniki, Greece, 2015. – Abstract book
3. Miloševic I, Korac M, Marković M, Popović N, Ilić M, **Jegorović B**, Grebenarević J, Tošić T, Varagić Z, Jovanović M. Concurrent infections in patients with C. difficile infection. 6th Eurasia Congress of Infectious Diseases (EACID), Beograd, 2014. abstract book, 212.
4. Milosevic I, Popovic N, Markovic M, Ilic M, **Jegorovic B**, Jankovic M, Markovic A, Korac M. Is leukocytosis an important marker of disease severity in patients with Clostridium difficile infection? 5th Southeast European Conference on Chemotherapy and Infection. Bled, Slovenia, October 2014., abstract book, 175.
5. Korac M, Popovic N, Markovic M, Ilic M, **Jegorovic B**, Jankovic M, Markovic A, Milosevic I. Prognostic factors for Clostridium difficile infection. 5th Southeast European Conference on Chemotherapy and Infection. Bled, Slovenia, October 2014., abstract book, 176.
6. **Jegorović B**, Dimić J, Škorić D. Acute lymphoblastic leukemia as a differential diagnosis of mononucleosis-like illness with negative viral serologies. 39th Annual Meeting of The European Society for Pediatric Infectious Diseases (ESPID); Online/Geneva 2021, abstract book, 620.
7. Dimić J, **Jegorović B**, Škorić D. HHV-6 status in all children diagnosed with cancer ― necessary or not? 39th Annual Meeting of The European Society for Pediatric Infectious Diseases (ESPID); Online/Geneva 2021, abstract book, 643.

**IZVOD U ZBORNIKU NACIONALNOG SKUPA**

1. **Jegorović B**. Šabanović M, Nikolić N, Katanić N, Obradović D, Poluga J. Komplikovana neurotuberkuloza nakon primene biološke terapije. Infekcije kod imunosuprimiranih osoba – problemi prepoznavanja, dijagnostike i lečenja. Beograd, 19-20. aprila 2024. Knjiga apstrakata, str. 33
2. Katanić N, Poluga J, **Jegorović B**, Šabanović M, Milić M. Kriptokokni meningoencefalitis kod non HIV imunodeficijencije. Infekcije kod imunosuprimiranih osoba – problemi prepoznavanja, dijagnostike i lečenja. Beograd, 19-20. aprila 2024. Knjiga apstrakata, str. 33
3. Opavski N, Mijac V, Gajić I, Grego E, Kekić D, **Jegorović B**, Ranin L. Trendovi rezistencije Streptococcus pyogenes i Streptococcus pneumoniae na antibiotike u Srbiji. X Kongres mikrobiologa Srbije – MIKROMED 2015, Beograd, Knjiga sažetaka (elektronska forma), 47. strana.
4. Kekić D, **Jegorović B**, Gajić I, Opavski N, Stojković M, Tomanović S, Stefanović S, Ranin L. Osetljivost grupe B streptokoka na antibiotike u četvorogodišnjem periodu (2010-2014.) u Beogradu. X Kongres mikrobiologa Srbije – MIKROMED 2015, Beograd, Knjiga sažetaka (elektronska forma), 194. strana.
5. **Jegorović B**, Kekić D, Travar M, Jovanović S, Ranin L. Komparativna analiza disk difuzionog metoda i E-testa u ispitivanju osetljivosti multirezistentnih sojeva bakterija roda Acinetobacter na tigeciklin. X Kongres mikrobiologa Srbije – MIKROMED 2015, Beograd , Knjiga sažetaka (elektronska forma), 192. strana.
6. **Jegorović B**. Dijagnostički i prognostički značaj trombocitopenije u malariji, 52. Kongres studenata biomedicinskih nauka 2011. godine, Budva, Crna Gora, Knjiga sažetaka (elektronska forma), 632. strana.
7. **Jegorović B**. Terapija visceralne lajšmanoze, 53. Kongres studenata biomedicinskih nauka 2012. godine, Kopaonik, Knjiga sažetaka (elektronska forma), 218. strana.

**POGLAVLJA U KNJIGAMA**

1. Redaktor poglavlja 196, 232, 234, 245e-260 u udžbeniku „Harisonovi principi interne medicine“, prevod sa engleskog jezika 19. izdanja knjige, Data Status, 2020. godine.
2. Autor poglavlja „Mijaza“ i „Larva migrans“, u knjizi „Atlas infektivnih bolesti“, autora Prof. dr Eleonore Gvodenović iz 2016. godine.

**b) Učešće na projektima**

Istraživač-saradnik u periodu od 2013. do 2015. godine na projektu Ministarstva nauke i prosvete Srbije pod br. 175039, naziv projekta: „Bakterije rezistentne na antibiotike u Srbiji: fenotipska i genotipska karakterizacija“, rukovodilac projekta prof. dr Lazar Ranin.

**c) Citiranost**

Prema podacima sa *Scopus*, radovi sa JCR liste u kojima je kandidat bio autor ili koautor citirani su u 107 navrata, h-index 4.

**Đ. OCENA O REZULTATIMA NAUČNOG I ISTRAŽIVAČKOG RADA**

Dr Boris Jegorović je uz ostalu dokumentaciju priložio spisak i fotokopije navedenih naučnih radova. Navedeno je ukupno 28 publikacija i to 14 radova objavljenih *in extenso*, a od toga je 11 radova sa JCR liste (u 3 rada je prvi autor, a u ostalim radovima je koautor).

Na osnovu priloženih publikacija može se zaključiti da su interesovanja kandidata vezana za različite oblasti infektologije. Najviše pažnje u svojim istraživanjima posvetio je dijagnostici i lečenju različitih infektivnih bolesti i neuroinfekcijama, dok je deo naučnog rada posvetio temama iz različitih oblasti infektologije: infekcijama imunokompromitovanih, epidemiologiji, tropskim bolestima, itd.

**E. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE**

Dr Boris Jegorović savesno i odgovorno učestvuje u radu i izvođenju nastavnih aktivnosti na Medicinskom fakultetu Univerziteta u Beogradu.

**Stručno-profesionalni doprinos**

Doktor Boris Jegorović je angažovan u Odeljenju za nejasna febrilna stanja, tropske bolesti i karantin Klinike za infektivne i tropske bolesti, UKCS, gde sa posvećenošću zbrinjava pacijente obolele od kontagioznih infekcija, poput gripa i COVID-19, kao i tropskih bolesti, uključujući malariju i dengu. Svakodnevno doprinosi radu ambulante za tropske bolesti pri ovom odeljenju, sa posebnim fokusom na parazitske infekcije, tropske bolesti i nejasna febrilna stanja, pokazujući izuzetnu stručnost u ovim oblastima. U svom radu koristi point-of-care ultrazvuk, čime unapređuje dijagnostiku i praćenje pacijenata. Kao deo tima Odeljenja za intenzivnu negu uključen je u terapijske procedure kao što su intubacija, invazivna i neinvazivna mehanička ventilacija kritično obolelih pacijenata. Svojim angažmanom unapredio je zbrinjavanje poremećaja balansa tečnosti i elektrolita, ne samo u Odeljenju za intenzivnu negu, već i na drugim odeljenjima, podižući ukupan kvalitet nege pacijenata. Pored posvećene edukacije studenata, nesebično prenosi znanje mlađim kolegama, negujući principe medicine zasnovane na dokazima kroz svakodnevnu praksu. Pored pomenutog, aktivno učestvuje i u lečenju bolesnika sa ostalim infektivnim i tropskim bolestima.

**Doprinos široj i akademskoj zajednici**

Član je Srpskog lekarskog društva, Sekcije infektologa.

**Saradnja sa drugim visokoškolskim, naučnoistraživačkim ustanovama u zemlji i inostranstvu**

Doktor Boris Jegorović je od juna 2024. godine nosilac renomirane Diplome iz tropske medicine i higijene (Diploma in Tropical Medicine and Hygiene; Pass with Distinction) koju izdaje prestižno udruženje Worshipful Society of Apothecaries, London. Nosilac je sertifikata o završenom kursu „Global Health and Humanitarian Medicine Course“ u trajanju od 10 meseci, od maja 2024. godine koji je organizovan od strane međunarodne organizacije Lekari bez granica (Medicins Sans Frontiers/Doctors Without Borders).

Dr Boris Jegorović je održao 3 predavanja po pozivu na akreditovanim nacionalnim skupovima:

1. Gostujući predavač - „Biomarkeri sepse – istine i zablude“, nacionalni simpozijum „Sepsa i infekcije krvi“, 26-28. maj 2023. godine, Divčibare, Organizator: Udruženje infektologa Srbije
2. Gostujući predavač - Srpsko lekarsko društvo. Sekcija za infektivne bolesti. Sekcija za istoriju medicine. “Dani sećanja na medicinara Luku Subotića”. Predavanje na temu: Stare infektivne bolesti – nova pretnja? Primer epidemije plućne kuge. Decembar 2017. godine.
3. Gostujući predavač - Srpsko lekarsko društvo. Sekcija za infektivne bolesti. Sekcija za istoriju medicine. “Dani sećanja na medicinara Luku Subotića”. Predavanje na temu: Pegavi tifus u srbiji - skriveni neprijatelj u ratovima sa početka 20. veka. Decembar 2019. godine.

**4. KANDIDAT dr Marko Marković, doktor medicinskih nauka, specijalista infektologije**

**A. OSNOVNI BIOGRAFSKI PODACI**

– Ime, srednje ime i prezime: Marko (Dobrivoje) Marković

– Datum i mesto rođenja: 02.09.1985, Beograd

– Ustanova gde je zaposlen: Klinika za infektivne i tropske bolesti UKCS

– Zvanje/radno mesto: lekar specijalista infektivnih bolesti

– Naučna oblast: infektivne bolesti

**B. STRUČNA BIOGRAFIJA, DIPLOME I ZVANJA**

**Osnovne studije:**

– Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu

– Mesto i godina završetka: Beograd, Septembar 2010.godine godine

– Prosečna ocena: 8,50.

**Doktorske studije:**

– Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu

– **Mesto i godina odbrane i članovi komisije: Beograd,** 01.10.2024.godine, komisija Prof. dr Goran Stevanović, Prof. dr Tatjana Đukić, Prof. dr Marko Ercegovac, Prof. dr Daniela Marić, Doc. dr Vesna Ćorić

–Mentori: Prof. dr Jovan Ranin i Prof. dr Marija Matić

– Naziv disertacije: „Povezanost markera inflamacije i polimorfizama gena za proteine uključene u regulaciju redoks homeostaze sa težinom kliničke slike i prognozom toka bolesti kod bolesnika sa COVID-19“

-Uža naučna oblast: infektivne bolesti

**Specijalizacija:**

– Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu

– Oblast specijalizacije: Infektologija

– Mesto i godina završetka, ocena i članovi komisije: Beograd, 2020.god, ocena 5, komisija: Prof. Dr Branko Milošević, Prof. Dr Jovan Ranin, Prof. Dr Ivana Milošević

**Uža specijalizacijia:**

- Naziv ustanove: Medicinski fakultet, Univerzitet u Beogradu

* Mesto, godina završetka i članovi komisije- u toku
* Naslov rada uže specijalizacije: Nije određwn
* Uža naučna oblast: Intenzivna medicina

**Dosadašnji izbori u nastavna i naučna zvanja**

* 2021.godine izabran Kliničkog asistenta na Medicinskom fakultetu Univerziteta u Beogradu, na predmetu Infektivne bolesti

**V. OCENA O REZULTATIMA PEDAGOŠKOG RADA**

Klinički asistent dr sci med. Marko Marković je od 2021.godine angažovan kao klinički asistent u izvođenju praktične nastave iz oblasti infektivnnih bolesti za studente na osnovnim studijama Medicinskog fakulteta Univerziteta u Beogradu, sa punim fondom časova predviđenim za nastavni program. Od strane studenata ocenjen je ocenom 4,72 tokom prve izborne godine.

**G. OCENA REZULTATA U OBEZBEĐIVANJU NAUČNO-NASTAVNOG PODMLATKA**

Mentor je studentkog radaIntegrisanih akademskih studija, Medicinskog fakulteta u Beogradu - rad pod nazivom: “Sifilis kod osoba koje žive sa HIV om u Srbiji”, prihvaćen je i u toku je izrada istog.

**D. NAUČNI I STRUČNI RAD**

**a) Spisak objavljenih naučnih i stručnih radova**

**ORIGINALNI RADOVI IN EXTENSO U ČASOPISIMA SA JCR (JOURNAL CITATION REPORTS) LISTE**

1. **Markovic M**, Ranin J, Bukumiric Z, Jerotic D, Savic-Radojevic A, Pljesa-Ercegovac M, Djukic T, Ercegovac M, Asanin M, Milosevic I, Stevanovic G, Simic T, Coric V, Matic M. GPX3 Variant Genotype Affects the Risk of Developing Severe Forms of COVID-19. Int J Mol Sci. 2023 Nov 10;24(22):16151. doi: 10.3390/ijms242216151. (**М21, IF 5,6**)
2. Milošević I, Todorovic N, Filipovic A, Simic J, **Marković M**, Stevanović O, Malinić J, Katanić N, Mitrović N, Nikolić N. HCV and HCC Tango – Deciphering the Intricate Dance of Disease: A Review Article. Int J Mol Sci, 2023 Nov 7;24(22):16048. doi: 10.3390/ijms242216048. (**M21, IF 5,6**)
3. Korać M, Rupnik M, Nikolić N, Jovanović M, Tošić T, Malinić J, Mitrović N, **Marković M**, Vujović A, Peruničić S, Bojović K, Djordjević V, Barać A, Milošević I. *Clostridioides difficile* ribotype distribution in a large teaching hospital in Serbia. Gut Pathog. 2020;12:26. doi: 10.1186/s13099-020-00364-7. (**M22, IF 4,181**)
4. Karic U, Pesic-Pavlovic I, Stevanovic G, Korac M, Nikolic N, Radovanovic-Spurnic A, Barac A, Mitrovic N, Markovic A, **Markovic M**, Petkovic A, Ostojic I, Perunicic S, Kekic N, Glidzic M, Djonin-Nenezic M, Brmbolic B, Milosevic I (2018) FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country’s perspective in DAA era. J Infect Dev Ctries.2018;12:178-182. doi: 10.3855/jidc.10190 (**M23, IF 1,175**)
5. Korac M, Milosevic I, **Markovic M**, Popovic N, Ilic M, Markovic A, Nikolic J, Jevtovic D (2015) Clostridium difficile infection: a Serbian single-center experience. J Infect Dev Ctries 2015 Feb 19;9(2):136-40. doi: 10.3855/jidc.5060 (**M23, IF 1,139**)

**CEO RAD U ČASOPISU KOJI NIJE UKLJUČEN U GORE POMENUTE BAZE PODATAKA**

1. **Marković Marko.** The role of disturbed redox homeostasis in COVID-19. Medicinski podmladak. 76(6). Vol. 76 br. 6. (2025). doi 10.5937/mp76-49373
2. Zlatko Perišić, Marina Đikić, Marija Laban Lazović, **Marko Marković**, Marija Milenković. Upotreba mobilnog telefona u vožnji? Medicinski Glasnik 2020. Vol 25, br 78; 40-45.
3. Karić U, Katanić N, Peruničić S, Mitrović N, Nikolić N, **Marković M**, Bojović K, Malinić J, Poluga J, Simonović-Babić J. Herpes zoster: Is there a need for new treatment recommendations?. Vojnosanitetski pregled. 2019; 76(11):1147-1152. (M23, IF 0,152)
4. N. Popović, **M. Marković,** V. Sabljak, A. Mandruš, I. Petrov-Bojičić, B. Milošević. Nadoknada i izbor tečnosti kod opekotina. Serbian Journal of Anesthesia and Intensive Therapy. 2013; 35(3-4):175-181. M52

**IZVOD U ZBORNIKU NARODNOG SKUPA**

1. **Markovic M**, Coric V, Bukumiric Z, Djukic T, Jerotic Dj, Savic-Radojevic A, Pljesa-Ercegovac M, Asanin M, Ercegovac M, Milosevic I, Stevanovic G, Simic T, Ranin J, Matic M. Značaj laboratorijskih parametara u identifikaciji COVID-19 pacijenata pod rizikom za progresiju COVID-19. Knjiga apstrakta. Drugi kongres kliničkih biohemičara i specijalista laboratorijske medicine Srbije sa međunarodnim učešćem. Beograd, Srbija, novembar 2022. М64

**IZVOD U ZBORNIKU MEĐUNARODNOG SKUPA**

1. Dragovic G, Zulevic J, Dimitrijevic B, Salemovic D, Ranin J, **Markovic M**, Jevtovic Dj. Adherence to cART in Serbia – an issue of concern? 16th European AIDS Conference. Milan, Italy, October 2017. М32
2. Dragovic G, Dimitrijevic B, Kusic J, Salemovic D, Ranin J, **Markovic M**, Smith C, Jevtovic Dj. Life expectancy in a low-middle income setting: a Belgrade Cohort. 16th European AIDS Conference. Milan, Italy, October 2017. М32
3. Popovic N, Milosevic I, Prostran M, Delic D, Nesic Z, **Markovic M**, Korac M. Comparison of treatment outcomes in patients with Clostridium difficile infection treated with Vancomycin and Vancomycin and Metronidazole combination therapy. 5th Southeast European Conference on Chemotherapy and Infection. Bled, Slovenia, October 2014. М32
4. **Markovic M**, Jankovic M, Popovic N, Markovic A, Pelemis M, Stevanovic G, Milosevic I, Korac M. The relation between the amount of inflammation and intensity of malabsorption in patients with pseudomembranous colitis. 5th Southeast European Conference on Chemotherapy and Infection. Bled, Slovenia, October 2014. М32
5. Milosevic I, Popovic N, **Markovic M**, Ilic M, Jegorovic B, Jankovic M, Markovic A, Korac M. Is leukocytosis an important marker of disease severity in patients with Clostridium difficile infection? 5th Southeast European Conference on Chemotherapy and Infection. Bled, Slovenia, October 2014. М32
6. Korac M, Popovic N, **Markovic M**, Ilic M, Jegorovic B, Jankovic M, Markovic A, Milosevic I. Prognostic factors for Clostridium difficile infection. 5th Southeast European Conference on Chemotherapy and Infection. Bled, Slovenia, October 2014. М32

**b) Citiranost:** Prema podacima sa Kobsona, radovi sa JCR liste u kojima je kandidat bio autor ili koautor citirani su u 27 navrata.

**Đ. OCENA O REZULTATIMA NAUČNOG I ISTRAŽIVAČKOG RADA**

Klinički asistent dr sci med Marko Marković je uz ostalu dokumentaciju priložio spisak i fotokopije publikacija. Navedeno je ukupno publikacija, i to 9 radova i 6 izvoda. Od ukupno 9 objavljenih radova objavljenih, 5 je sa JCR liste, u kojima je dr Marko Marković saradnik. Ukupan IF objavljenih radova kandidata je 5,74. Pored originalnih radova publikovanih u celosti, kandidat je objavio i 6 izvoda u zborniku međunarodnog skupa. Na osnovu priloženog, kandidat ima kontinuitet u bavljenju naučnoistraživačkim radom uz istovremeno stručno usavršavanje na Klinici za infektivne i tropske bolesti Univerzitetskog Kliničkog Centra Srbije. Dosadašnje teme publikovanih članaka su iz različitih oblasti infektologije, što govori u prilog svestranosti interesovanja kandidata. Među publikovanim naučnim radovima zastupljene su gotovo sve oblasti infektologije. Tokom prethodnog izbornog perioda u zvanju Kliničkog asistenta objavio je nekoliko novih publikacija iz oblasti infektivnih bolesti., a tokom poslednje dve godine kandidat je bio angažovan na izradi doktorske disertacije pod mentorstvom Prof. dr Jovana Ranina i Prof. dr Marije Matić, pod nazivom „Povezanost markera inflamacije i polimorfizama gena za proteine uključene u regulaciju redoks homeostaze sa težinom kliničke slike i prognozom toka bolesti kod bolesnika sa COVID-19“, koju je odbranio 01.10.2024.godine.

**E. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE**

Dr Uroš Karić savesno i odgovorno učestvuje u radu i izvođenju nastavnih aktivnosti na Medicinskom fakultetu Univerziteta u Beogradu.

**Stručno-profesionalni doprinos**

Tokom prethodnog izbornog perioda dr Marko Marković je bio angažovan kao klinički asistent u izvođenju praktične nastave iz oblasti infektivnnih bolesti za studente na osnovnim studijama Medicinskog fakulteta Univerziteta u Beogradu i od strane studenata ocenjen je ocenom 4,72 tokom prve izborne godine. Mentor je jednog studentskog rada čija je izrada u toku. Takođe je učestvovao u različitim akreditovanim stručnim skupovima koji su za temu imali aktuelnosti iz infektivnih bolesti.

**Doprinos akademskoj i stručnoj zajednici**

Pored angažovanja u svojstvu kliničkog asistenta, dr Marko Marković je član Srpskog lekarskog društva, HIV Asocijacije Srbije, (HIVAS) i Nacionalne Komisije za borbu protiv HIV-a i tuberkuloze.

**5. Kandidat dr UROŠ KARIĆ, specijalista infektologije**

**A. OSNOVNI BIOGRAFSKI PODACI**

–Ime, srednje ime i prezime: Uroš (Rajko) Karić

–Datum i mesto rođenja: 03.01.1989, Lazarevac, Srbija

–Ustanova gde je zaposlen: Klinika za infektivne i tropske bolesti, Univerzitetski klinički centar Srbije

–Zvanje / radno mesto: klinički asistent, lekar specijalista infektolog

–Uža naučna oblast: infektivne bolesti

**B. STRUČNA BIOGRAFIJA, DIPLOME I ZVANJA**

**Osnovne studije**

–Naziv ustanove: Medicinski fakultet u Beogradu

–Mesto i godina završetka, prosečna ocena: Beograd, 2014. godina, prosečna ocena 9,14

**Doktorske studije**

–Naziv ustanove: Medicinski fakultet Univerziteta u Beogradu

–Mentor: prof. dr Branko Milošević

–Naziv disertacije: nije određen.

–Uža naučna oblast: mikrobi i infekcija

–Status: upisao završnu godinu doktorskih studija; nema prijavljenu temu.

**Specijalizacija**

–Naziv: Medicinski fakultet Univerziteta u Beogradu

–Mesto i godina završetka, ocena i članovi komisije: Beograd, 2021. godina, ocena 5; komisija: prof. dr Miloš Korać - predsednik, prof. dr Branko Milošević, prof. dr Goran Stevanović

**Uža specijalizacija**

–Naziv: Medicinski fakultet Univerziteta u Beogradu

–Mesto i godina završetka, ocena i članovi komisije: Beograd, 2023. godina, ocena: odličan; komisija: doc. dr Snežana Aranđelović - predsednik, prof. dr Branko Milošević, prof. dr Branka Bonači Nikolić – mentor

–Naslov rada uže specijalizacije: ,,Učestalost i značaj antinukleusnih i antineutrofilnih citoplazmatskih antitela kod pacijenata sa febrilnim stanjem nejasne etiologije”

–Uža naučna oblast: Alergologija i klinička imunologija

**Dosadašnji izbori u nastavna i naučna zvanja**:

U nastavno zvanje klinički asistent izabran je 5.7.2022 za užu naučnu oblast Infektivne bolesti na Medicinskom fakultetu Univerziteta u Beogradu

**V. OCENA O REZULTATIMA PEDAGOŠKOG RADA**

Doktor Uroš Karić učestvuje u izvođenju nastave održavajući vežbe redovne nastave za studente sedmog i osmog semestra (240 časova godišnje) na Integrisanim akademskim studijama medicine za sticanje akademskog naziva doktor medicine, Medicinskog fakulteta Univerziteta u Beogradu. Sarađivao je u više navrata sa Centrom za stručni i naučno-istraživački rad studenata, kao mentor i recenzent studentskih radova. Kandidat takođe redovno učestvuje u izvođenju praktične nastave na engleskom jeziku. Uključen je i u izvođenje praktične nastave u okviru specijalističke nastave iz oblasti Infektivnih bolesti. Prema izveštaju Centra za obezbeđivanje kvaliteta, unapređenje nastave i razvoj medicinske edukacije Medicinskog fakulteta Univerziteta u Beogradu ocenjen je od strane studenata ocenom 4,91 za školsku 2022/2023. godinu i ocenom 4,97 za školsku 2023/2024. godinu.

**G. OCENA REZULTATA U OBEZBEĐIVANJU NAUČNO-NASTAVNOG PODMLATKA**

Dr Uroš Karić je mentor jednog nagrađenog studentskog rada pod nazivom ,,Nepneumokokni streptokok kao uzročnik neuroinfekcije”. Trenutno je mentor još jednog studentskog rada koji je u izradi.

**D. NAUČNI I STRUČNI RAD**

**a) Spisak objavljenih naučnih i stručnih radova**

**ORIGINALNI RADOVI INEXTENSO U ČASOPISIMA SA JCR (JOURNAL CITATION REPORTS) LISTE:**

1. Jankovic J, Stjepanovic M, Milenkovic M, Radoncic D, Bisevac G, Mandic S, Laban M, Jandric A, Djikic M, **Karic U**, Hadzibegovic A, Ercegovac M. Differences in pulmonary and extra-pulmonary causes of hemoptysis. Reveduc-Madrid. 2024;406(11):107–19, M22, IF 2.
2. Dokić M, Milošević B, Bila J, Šljivančanin D, **Karić U**, Beleslin A. Impact of COVID-19 pandemic on changing the ratio of abdominal, vaginal, and laparoscopic hysterectomies. Srpskiarhivzacelokupnolekarstvo. 2024;152(5–6):254–8, M23, IF 0,2.
3. Nikolić N, Poluga J, Milošević I, Todorović N, Filipović A, Jegorović B, Mitrović N, **Karić U**, Gmizić I, Stevanović G, Milošević B. Neurological and neuromuscular manifestations in patients with West Nile neuroinvasive disease, Belgrade area, Serbia, season 2022. Neurol Sci. 2024 Feb 1;45(2):719–26, M22, IF 2,7.
4. Jankovic J, Djurdjevic N, Jandric A, **Karic U**, Milivojevic I, Ratkovic A, Buha I. The influence of gender differences on the illness perception and women’s point of view on COPD. BratislLekListy. 2023;124(11):787–801, M23, IF 1,5.
5. Stefanovic S, Werner E, Gerigk M, Hornung R, **Karic U**, WEIß C, Tuschy B, Berlit S, Sütterlin M. Therapy Guidance by Vaginal Smears of Pregnant Women With Preterm Complications in Correlation With Maternal and Neonatal Outcome: A Retrospective Analysis. In Vivo. 2023 May 1;37(3):1211–8, M23, IF 1,8.
6. Stefanovic S, Wirtz R, Sütterlin M, **Karic U,** Schneeweiss A, Deutsch TM, Wallwiener M. Cut-off Analysis of HLA-A and HLA-B/C Expression as a Potential Prognosticator of Favorable Survival in Patients With Metastatic Breast Cancer. Anticancer Research. 2023 Apr 1;43(4):1449–54, M23, IF 1,6.
7. Marasco G, Cremon C, Barbaro MR, Cacciari G, Falangone F, Kagramanova A, et al (…**Karic U**…). Post COVID-19 irritable bowel syndrome. Gut. 2023 Mar 1;72(3):484–92, M21a, IF 21,1, ½ 10,6.
8. Marasco G, Cremon C, Barbaro MR, Salvi D, Cacciari G, Kagramanova A, et al (…**Karic U**…). Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. Official journal of the American College of Gastroenterology | ACG. 2022 Jan;117(1):147, M21, IF 10,2, ½ 5,1.
9. **Karić U**, Milošević I, Pešić-Pavlović I, Salemović D, Stojković M, Jevtović D. The treatment outcome of chronic HBV infection among HBV/HIV co-infected and HBV mono-infected patients. Int J STD AIDS. 2020 Jan 1;31(1):38–45, M23, IF 1,359.
10. **Karić U**, Katanić N, Peruničić S, Mitrović N, Nikolić N, Marković M, Bojović K, Malinić J, Poluga J, SimonovićBabić J. Herpes zoster - is there a need for new treatment recommendations? Vojnosanitetskipregled. 2019;76(11):1147–52, M23, IF 0,152.
11. Poluga J, **Karić U**, Dakić Z, Katanić N, Lavadinović L, Milošević B, Nikolić N, Urošević A, Jegorović B, Pavlović M. Severe imported malaria in a Serbian referral center. Vojnosanitetskipregled. 2019;76(5):470–5, M23, IF 0,152.
12. **Karic U**, Pesic-Pavlovic I, Stevanovic G, Korac M, Nikolic N, Radovanovic-Spurnic A,Barac A, Mitrovic N, Markovic A, Markovic M, Petkovic A, Ostojic I, Perunicic S, Kekic N, Glidzic M, Djonin-Nenezic M, Brmbolic B, Milosevic I. FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C – a developing country’s perspective in DAA era. The Journal of Infection in Developing Countries. 2018 Mar 31;12(03):178–82, M23, IF 1,175.
13. Milošević I, **Karić U**, Pešić-Pavlović I, Stevanović G, Barać A, Smiljanić M, Arsenović A, Stevanović O, Đonin-Nenezić M, Brmbolić B. Successful treatment of chronic hepatitis C in a hemodialysis. The Journal of Infection in Developing Countries. 2018 Feb 28;12(02):142–5, M23, IF 1,175.
14. Stefanovic S, Wallwiener M, **Karic U**, Domschke C, Katic L, Taran FA, Pesic A, Hartkopf A, Hadji P, Teufel M, Schuetz F,Sohn C, Fasching P, Schneeweiss A, Brucker S. Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications. Support Care Cancer. 2017 Feb 1;25(2):549–58, M21, IF 2,676.

**RADOVI U ČASOPISU ,,MEDICINSKA ISTRAŽIVANJA”**

1. Mitrović N, Nikolić N, Filipović A, Vujović A, **Karić U**, Šabanović M, Milošević The impact of chronic viral hepatitis on COVID-19: Clinical course and risk factors for poor outcome. Medicinskaistraživanja. 2024;57(2):65–73.

**CEO RAD U ČASOPISU KOJI NIJE UKLJUČEN U GORE POMENUTE BAZE PODATAKA**

1. **Karić U,** Petković KA, Jegorović B, Šabanović M, Petković S, Katanić N, Poluga J. Tick-borne infections. Galenika Medical Journal. 2024;3(11):73–9.

2. Brmbolić B, Grebenarović J, **Karić U**. Complicated Ulceroglandular Tularemia. Journal of Global Infectious Diseases. 2022 Sep;14(3):120.

3. Nikolić N, Jovanović J, **Karić U,** Ostojić I, Jegorović B, Marković M, Mitrović N, Milošević I, Milošević B. Kliničke karakteristike i faktori rizika za smrtni ishod kod bolesnika sa COVID-19 lečenih u jedinici intenzivne nege. Svet rada. 2022; 2:371-383.

**c) Citiranost**

Prema podacima sa *Scopus*, radovi sa JCR liste u kojima je kandidat bio autor ili koautor citirani su u 125 navrata.

**Đ. OCENA O REZULTATIMA NAUČNOG I ISTRAŽIVAČKOG RADA**

Dr Uroš Karić je uz ostalu dokumentaciju priložio spisak i fotokopije svih navedenih radova. Navedeno je ukupno 18 publikacije i to 18 radova objavljenih *in extenso*, a od toga je 14 radova sa JCR liste (u 3 rada je prvi autor, a u ostalim radovima je koautor).

Na osnovu priloženih publikacija može se zaključiti da su interesovanja kandidata vezana za različite oblasti infektologije. Najviše pažnje u svojim istraživanjima posvetio je oboljenjima jetre – akutnim i hroničnim virusnim hepatitisima. Izuzev ove problematike, u naučnoistraživačkom radu nalaze se i publikacije iz drugih različitih oblasti infektologije: infekcije centralnog nervnog sistema, zoonoze, HIV medicina, itd.

**E. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE**

Dr Uroš Karić savesno i odgovorno učestvuje u radu i izvođenju nastavnih aktivnosti na Medicinskom fakultetu Univerziteta u Beogradu.

**Stručno-profesionalni doprinos**

Radi u odeljenju Hepatitis II Klinike za infektivne i tropske bolesti, UKCS i deo je tima za lečenje akutnih i hroničnih hepatitisa i drugih infektivnih bolesti jetre. Svakodnevno učestvuje u radu hepatološke ambulante kroz koju godišnje bude pregledano više hiljada pacijenata sa akutnim i hroničnim virusnim bolestima jetre. Angažovan je u sprovođenju dijagnostičkih procedura poput ultrazvučnih pregleda, a radeći i kao deo tima Odeljenja za intenzivno lečenje angažovan je i u terapijskim procedurama intubacije i invazivne mehaničke ventilacije kritično obolelih pacijenata. Pored pomenutog, dr Uroš Karić aktivno učestvuje i u lečenju bolesnika sa ostalim infektivnim i tropskim bolestima.

**Doprinos akademskoj i široj zajednici**

Član je Srpskog lekarskog društva, Sekcije infektologa, Udruženja infektologa Srbije, , kao i Srpskog udruženja za antimikrobnu hemioterapiju.

**Saradnja sa drugim visokoškolskim, naučnoistraživačkim ustanovama u zemlji i inostranstvu**

Dr Uroš Karić održao je 4 predavanja po pozivu na akreditovanim nacionalnim skupovima:

1. Gostujući predavač - Encefalitis-aktuelnosti i diferencijalno-dijagnostičke dileme, Mart 2023, Sremska Kamenica, Srbije
2. Gostujući predavač - PRETEĆE INFEKTIVNE BOLESTI: da li smo spremini za nove evolutivne izazove? Mart 2023, Beograd, Srbija
3. Gostujući predavač i panelista - Dileme i kontroverze 7, April 2023, Novi Sad, Srbija
4. Gostujući predavač - From Biotechnology to Human and Planetary Health, April 2024, Beograd, Srbija